[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Numed Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":170},{"warningLetters":4,"total":169},[5,31,50,69,88,101,123,145],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1295,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-08-27T13:20:00Z\">08\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-20T04:00:00Z\">08\u002F20\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanumed-international-llc-674310-08202024\">AnuMed International, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Finished Pharmaceutical\u002FUnapproved New Drug\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Julie R. Alcantar\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>AnuMed International, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3908 E Broadway Rd, Suite 110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85040-2995\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:julie@anumed-intl.com\"> julie@anumed-intl.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 20, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 674310\u003C\u002Fp>\n\n\u003Cp>Dear Julie Alcantar:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, AnuMed International, LLC, FEI 3010164449, at 3908 E Broadway Rd, Suite 110, Phoenix, Arizona from November 1 to 7, 2023.\u003C\u002Fp>\n\n\u003Cp>FDA also reviewed your website at the Internet address https:\u002F\u002Fwww.anumed-intl.com\u002F in February and April 2024 and has observed that your website offers “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser &amp; Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” products for sale in the United States. As described below, your above-mentioned products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, your “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)” products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>In addition, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B). We reviewed your November 28, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your product labeling obtained during FDA’s inspection and on your website, your “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser &amp; Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your product labeling and website https:\u002F\u002Fwww.anumed-intl.com\u002F that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Semaglutide Homeopathic Formula\u003C\u002Fu>\u003Cbr>\nOn the product label:\u003Cbr>\n• “CRAVINGS\u003Cbr>\nAPPETITE\u003Cbr>\nWEIGHT LOSS”\u003C\u002Fp>\n\n\u003Cp>• “INDICATIONS:\u003Cbr>\nIt may help to temporarily reduce minor hunger pangs and control appetite to support weight loss efforts.”\u003C\u002Fp>\n\n\u003Cp>• “DIRECTIONS: . . . For maximum effectiveness repeat 2 to 3 times per day until desired weight or craving control is achieved. Continue as needed if cravings arise and to help avoid weight regain.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Magnesium 50 mg Body Cream\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Highly Effective for Leg Cramps, Muscle Soreness, Nighttime Leg Discomfort, Inflammation Relief”\u003Cbr>\n• “Magnesium is important for many processes in the body. It helps regulate muscle and nerve function, blood sugar levels, blood pressure, making protein, bone and DNA. Studies have shown that deficiency of Magnesium results in cramping and several muscular pain.”\u003Cbr>\n• “Magnesium Chloride helps with the normal functioning of cells, nerves, bones, and the heart.”\u003Cbr>\n• “Niacin (vitamin B3) helps support the cardiovascular system and the heart. It contributes to healthy metabolic function, supports the pancreas, and works to support brain &amp; nerve function.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>AnuMed™ 25mg Per Pump PROGESTERONE CREAM and AnuMed™ 75mg Per Pump PROGESTERONE CREAM\u003C\u002Fu>\u003Cbr>\nOn the product label:\u003Cbr>\n• “75 mg Per Pump PROGESTERONE CREAM . . . Hormones \u002F Mood \u002F Sleep . . . Use 1 pump a day 1 to 3 minutes before a meal, or as recommended by your practitioner.”\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “\u003Cstrong>5 Benefits of Natural Progesterone Cream with ISO99:\u003C\u002Fstrong> . . . Relieves Menopause Symptoms . . . promote bone density . . . Boosts Fertility . . . preventing miscarriage. . . . Treats Fibroid Tumors . . . Helps Endometriosis . . . Balance Hormones and Relieve PMS Symptoms . . . Relieves Inflammation”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP and AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “\u003Cstrong>Natural Bio-Identical BIO-EST 2.5mg\u003C\u002Fstrong> may help with menopause symptoms. . . . \u003Cstrong>BENEFITS\u003C\u002Fstrong> . . . Lower the risk of urinary tract infections (UTIs) . . . Strengthen bones and prevent osteoporosis”\u003Cbr>\n• “\u003Cstrong>Natural Bio-Identical Bio-EST 5mg\u003C\u002Fstrong> may help with menopause symptoms. . . . \u003Cstrong>BENEFITS\u003C\u002Fstrong> . . . Lower the risk of urinary tract infections (UTIs) . . . Strengthen bones and prevent osteoporosis”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>AnuMed™ 2.5 All Natural ESTRIOL CREAM and AnuMed™ 5.0 All Natural ESTRIOL CREAM\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “\u003Cstrong>Natural Bioidentical Estriol Cream 2.5 with Hyaluronic Acid\u003C\u002Fstrong> . . . #1 Recommended Estriol Cream for Menopause Relief, Mood Swings, Hot Flashes, Breast soreness . . . Natural Hormone Balance”\u003Cbr>\n• “\u003Cstrong>Natural Bioidentical Estriol Cream 5.0 with Hyaluronic Acid\u003C\u002Fstrong> . . . #1 Recommended Estriol Cream for Menopause Relief, Mood Swings, Hot Flashes, Breast soreness . . . Natural Hormone Balance”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>AnuMed™ Bio-Identical DHEA 20 CREAM and AnuMed™ Bio-Identical DHEA 50 CREAM\u003C\u002Fu>\u003Cbr>\nFrom your storefront on Amazon’s webpage https:\u002F\u002Fwww.amazon.com\u002FANUMED-Bioidentical-Dehydroepiandrosterone-Hyaluronic-Essential\u002Fdp\u002FB0BNHH4R8Q?th=1\u003Cbr>\n• “ANUMED – All Natural Bioidentical DHEA 20mg Cream . . . for Hormone Balance, Mood, Immune System . . . Natural Balancing of Hormone Levels, Promotes Mood, Immune System, Anti-Aging, Energy, Metabolism.”\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “\u003Cstrong>All Natural Bioidentical DHEA 50mg Cream (Dehydroepiandrosterone) + Hyaluronic Acid . . . Hormone Balance, Mood, Energy, Immune System\u003C\u002Fstrong> . . . Natural Balancing of Hormone Levels. Promotes Mood, Immune System, Anti-Aging, Energy, Metabolism.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>50,000 IU Vitamin D3+K2 CREAM\u003C\u002Fu>\u003Cbr>\nOn the product label:\u003Cbr>\n• “With Hyaluronic Acid . . . May Increase Calcium Absorption . . . PSORIASIS &amp; ECZEMA RELIEF . . . May help relieve skin flares caused by Psoriasis &amp; Eczema. . . . Vitamin D is necessary for strong bones and teeth. . . . May Help muscle function &amp; support immune system. . . . May help heal wounds faster such as fading bruising.”\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Vitamin D3 50,000 IU cream is our most potent vitamin-based solution created with the intent of replenishing the lowest vitamin deficiencies and relieving the symptoms of various conditions such as psoriasis and eczema in a minimal time frame. It can help with boosting immune system.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser &amp; Digestive Health Support\u003C\u002Fu>\u003Cbr>\n• In the name of the product – “Parasite Cleanser”\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “A proprietary blend of herbals along with zinc to help fight and eliminate parasites in the body”\u003Cbr>\n• “Wormwood kills adult parasites and especially pinworms.”\u003Cbr>\n• “Black Walnut which has anti-fungal and antibacterial properties and can kill intestinal parasites like roundworm and tapeworm. It helps to clean out any toxins and dangerous pathogens.”\u003Cbr>\n• “Clove Bud kills the parasite eggs that may be lingering in the intestinal tract along with worms . . . Thus, helps relieve indigestion and constipation problems. . . . These compounds provide potent antiseptic and anti-inflammatory benefits.”\u003Cbr>\n• “Fennel is helpful in reducing diarrhea if it is caused by bacterial infection because some components of the essential oil in fennel such as anetol and cineole have disinfectant and antibacterial properties.” • “Ginger is known as an anti-parasitic. Researchers show that it can inhibit a variety of worms and parasites..”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Vitamin C Booster - 2000mg\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Best protection support from cold, flu [influenza], virus [viral infection]”\u003Cbr>\n• “Zinc may help with wound healting [sic]”\u003Cbr>\n• “L-Lysine . . . Also, may help people with the herpes simplex virus (HSV) [viral infection] and diabetes.”\u003Cbr>\n• “Ultimate Defense from cold, Flu [influenza], Virus [viral infection], allergy”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Immune Booster 90 Capsules\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Has Zinc for which . . . may help combat colds, upper respiratory infections and viruses [viral infection]. . . . This product not only boosts immune system to help make body strong in order to combat most viruses [viral infection] and infections”\u003Cbr>\nVegan Vitamin D3 K2 60ct Capsules\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Research studies have indicated that K2 intake can decrease bone loss among those with Osteoporosis.”\u003Cbr>\n• “Vitamin D deficiencies have been linked by researchers to . . . sleeping disorders.”\u003Cbr>\n• “Research has indicated that vitamin D, while in combination with other bodily properties, plays a pivotal role in fortifying the antibacterial potency of the essential immune cells.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Heart Disease: Research has found that B-12 in combination with B-6 and folic acid may help regulate and decrease the levels of homocysteine in the blood system, which are known to increase the chances of cardiovascular disease.”\u003Cbr>\n• “Dementia and Cognitive Abilities: . . . Research has indicated an association between low levels of B-12 and cognitive decline. As a result, the B-12 . . . solution may help support and replace the lack of the nutrient while improving cognitive function.”\u003Cbr>\n• “When the body has a deficiency of the vitamin, harmful bacteria begins to grow. A consistent intake of B-12 has demonstrated that it can help remove bad bacteria . . . and potentially prevent gastrointestinal disorders.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>2oz Vitamin C Booster Drops\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Has been recommended to try and help ease cold and flu [influenza] symptoms.”\u003Cbr>\n• “Be prepared for fighting illness and germs.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>2oz Anumed Zinc Drops\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Ultimate Defense from Cold, Flu [influenza], Virus [viral infection], Allergy”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Turmeric Curcumin Drops 775mg with Black Pepper Extract\u003C\u002Fu>\u003Cbr>\nOn the product webpage:\u003Cbr>\n• “Curcumin and other chemicals in turmeric might decrease swelling (inflammation). Because of this, turmeric might be beneficial for treating conditions that involve inflammation. Has been known to help with the reduction of inflammation, pain”\u003Cbr>\n\u003Cbr>\nYour “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” and “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser &amp; Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM” are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because the product labels and\u002For websites include statements that misleadingly suggest that the drug products are approved or endorsed by FDA in some way. For example, the website for Magnesium 50 mg Body Cream includes the image of a blue circle with the claim, “FDA * APPROVED * FACILITY.” Further, the product labels and\u002For websites for the other seven before-listed products include statements that these products are made or manufactured in an “FDA inspected and Certified Facility,” a “Certified FDA registered facility,” and\u002For a “FDA registered facility.” FDA’s regulations provide that “[r]egistration of an establishment or listing of a drug does not denote approval of the establishment, the drug, or other drugs of the establishment, nor does it mean that a product may be legally marketed” (21 CFR 207.77(a)). However, the general public is not likely to be familiar with the details of FDA’s regulations. The above assertions misleadingly suggest that the above-mentioned drug products are approved or endorsed by FDA in some way. Your “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM” products are not the subjects of an FDA-approved application. Therefore, these products are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because their labeling is false or misleading. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Additionally, a drug is misbranded under section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act, 21 U.S.C. 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” and “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)” are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your before-noted products fail to bear adequate directions for their intended uses and, therefore, are misbranded under section 502(f)(1) of the Act, 21 U.S.C. 352(f)(1). The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to perform adequate identity testing, including specific identity testing as appropriate, for each shipment of each lot of components, such as glycerin and ethyl alcohol (ethanol; alcohol), used in the manufacture of your drug products. During the inspection, you indicated that you were not aware testing was required and that you rely upon your supplier’s certificate of analysis (COA) for acceptance of incoming materials.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Alcohol (Ethanol)\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Identity testing for pharmaceutical alcohol (ethanol and isopropyl alcohol) includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem> at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Identity testing for glycerin and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you are reviewing options for identity testing of raw materials. Your response is inadequate because you did not provide sufficient detail or evidence of corrective actions (e.g., assessing retain samples).\u003C\u002Fp>\n\n\u003Cp>Without appropriate testing of components, you cannot ensure the quality and safety of your drug products.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003Cbr>\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003Cbr>\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003Cbr>\n• A commitment to provide test results for components used in the manufacture of your drug products, no later than 30 calendar days from the date of this letter, including testing retains for all lots of drug components at high-risk for DEG and EG contamination, and pharmaceutical alcohol for methanol contamination. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG, EG, and methanol.\u003C\u002Fp>\n\n\u003Cp>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG, EG, or methanol contamination (including, but not limited to, glycerin and ethyl alcohol). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG, EG, or methanol including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Lack of Process Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately validate your processes used to manufacture your drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that your process validation procedure will be reviewed and personnel trained. However, your response is inadequate as you did not provide sufficient detail or evidence of corrective actions.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Water System\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm uses water as a component to manufacture your drug products. You failed to adequately qualify your purified water system. You also failed to show that your water system is adequately monitored to ensure it consistently produces water that meets appropriate microbial limits. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that your quality unit will begin conducting regular inspections to ensure the water system is adequate. However, your response is inadequate as you did not provide sufficient detail or evidence of corrective actions.\u003C\u002Fp>\n\n\u003Cp>Purified water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\n\n\u003Cp>Furthermore, you manufacture drug products (including hormones) and non-pharmaceutical products (e.g., cosmetics) using shared equipment (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> tanks, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and filling lines). In your response, you state that your cleaning validation procedure will be reviewed and revised to include the necessary cleaning validation studies. Adequate cleaning procedures are required as chemical and microbial residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003Cbr>\n• A timeline for performing PPQ for each of your marketed drug products.\u003Cbr>\n• Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003Cbr>\n• A comprehensive, independent assessment of your water system design, control, and maintenance.\u003Cbr>\n• A thorough remediation plan to assure you operate a suitable water system, including any redesign. Include a robust ongoing control, maintenance, and monitoring program to ensure the system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\u003Cbr>\n• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003Cbr>\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>\n&nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; o Maximum hold times before cleaning\u003Cbr>\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003Cbr>\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to validate your non-compendial microbial methods used to test drug products and assure the methods were equivalent to or better than USP methods. For example, you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> to analyze total count and yeast and mold in finished product. Additionally, you failed to follow the instructions for use and the investigator observed the use of expired \u003Cstrong>(b)(4)\u003C\u002Fstrong> test materials for finished product testing.\u003C\u002Fp>\n\n\u003Cp>In your response, you indicate that you ceased use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> non-compendial tests. Your response is inadequate as you did not provide sufficient detail or evidence of corrective actions, including validation or verification of appropriate microbial methods for drug product testing by your contract laboratory or your internal laboratory, and to demonstrate that the methods used are equivalent to or better than USP methods. You also did not commit to conducting retrospective review of products tested using your non-compendial, non-validated tests.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision. Include specifications for drug products within expiration that are already distributed within the United States and specifications for future drug products.\u003Cbr>\n&nbsp; o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>\n&nbsp; o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003Cbr>\n• Chemical and microbial test method verification or validation reports and supporting data for internal and contracted testing of your components and drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003Cbr>\n• An adequate system for retention of production, control, or distribution records associated for all batches of drug product (21 CFR 211.180(a)).\u003Cbr>\n• Batch production and control records include documentation of the accomplishment of each significant step in the manufacture and processing for each batch of drug product (21 CFR 211.188(b)).\u003Cbr>\n• Performance of periodic (i.e., at least annually) product reviews (21 CFR 211.180(e)).\u003Cbr>\n• Adequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. The QU must be accountable for implementing all the controls and reviewing the results of manufacture to ensure that product quality standards have been met. In smaller firms, it is recommended that another qualified individual, not involved in the production operation, conduct an additional, periodic review of QU activities. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003Cbr>\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection ending December 13, 2017, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>Your AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM, “AnuMed™ Bio-Identical DHEA 20 CREAM” and “AnuMed™ Bio-Identical DHEA 50 CREAM” drugs are hormone containing products that are deemed to be new drugs under a final determination issued under 21 CFR part 330, as published in the Federal Register on September 9, 1993 (see 58 FR 47610). There, the Agency has determined that any OTC drug product other than hydrocortisone that is labeled, represented, or promoted as a topically applied hormone-containing product for drug use are not generally recognized as safe and effective under section 201(p)(1) of the FD&amp;C Act and that all such products are deemed to be new drugs and require an approved new drug application under section 505 of the FD&amp;C Act to be lawfully marketed. 21 CFR 310.530.\u003C\u002Fp>\n\n\u003Cp>Furthermore, as an OTC combination psoriasis\u002Fskin protectant drug products, your “50,000 IU Vitamin D3+K2 CREAM” must conform to the conditions of use set forth in the Over-the-Counter Monograph M032: Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis for Over-the-Counter Human Use (henceforth “M032”), encompassed under the final administrative order OTC000021 and the Over-the-Counter Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”) encompassed under the final administrative order OTC000005. However, your “50,000 IU Vitamin D3+K2 CREAM” does not conform to conditions specified in either M032 or M016 because its labeling has intended uses such as, “PSORIASIS &amp; ECZEMA RELIEF” and “help heal wounds” that go beyond the general intended uses described in M032 and M016. Neither final order allows for such a combination of a psoriasis and a skin protectant. There is no basis under the FD&amp;C Act under which these products would be legally marketed without an approved application.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We recognize that the “Semaglutide Homeopathic Formula” labeling describes the products as being “homeopathic.”\u003C\u002Fp>\n\n\u003Cp>First, we note that under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your product includes semaglutide, which is not listed in the HPUS; thus, this product falls outside the scope of products addressed in this guidance.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJulie R. Alcantar\n\nRecipient Title\n\nOwner\n\nAnuMed International, LLC\n\n3908 E Broadway Rd, Suite 110\n\nPhoenix, AZ 85040-2995\n\nUnited States\n\njulie@anumed-intl.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nAugust 20, 2024\n\nRE: 674310\n\nDear Julie Alcantar:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, AnuMed International, LLC, FEI 3010164449, at 3908 E Broadway Rd, Suite 110, Phoenix, Arizona from November 1 to 7, 2023.\n\nFDA also reviewed your website at the Internet address https:\u002F\u002Fwww.anumed-intl.com\u002F in February and April 2024 and has observed that your website offers “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” products for sale in the United States. As described below, your above-mentioned products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, your “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)” products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nIn addition, because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B). We reviewed your November 28, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nUnapproved New Drugs\n\nBased on a review of your product labeling obtained during FDA’s inspection and on your website, your “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your product labeling and website https:\u002F\u002Fwww.anumed-intl.com\u002F that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\nSemaglutide Homeopathic Formula\n\nOn the product label:\n\n• “CRAVINGS\n\nAPPETITE\n\nWEIGHT LOSS”\n\n• “INDICATIONS:\n\nIt may help to temporarily reduce minor hunger pangs and control appetite to support weight loss efforts.”\n\n• “DIRECTIONS: . . . For maximum effectiveness repeat 2 to 3 times per day until desired weight or craving control is achieved. Continue as needed if cravings arise and to help avoid weight regain.”\n\nMagnesium 50 mg Body Cream\n\nOn the product webpage:\n\n• “Highly Effective for Leg Cramps, Muscle Soreness, Nighttime Leg Discomfort, Inflammation Relief”\n\n• “Magnesium is important for many processes in the body. It helps regulate muscle and nerve function, blood sugar levels, blood pressure, making protein, bone and DNA. Studies have shown that deficiency of Magnesium results in cramping and several muscular pain.”\n\n• “Magnesium Chloride helps with the normal functioning of cells, nerves, bones, and the heart.”\n\n• “Niacin (vitamin B3) helps support the cardiovascular system and the heart. It contributes to healthy metabolic function, supports the pancreas, and works to support brain & nerve function.”\n\nAnuMed™ 25mg Per Pump PROGESTERONE CREAM and AnuMed™ 75mg Per Pump PROGESTERONE CREAM\n\nOn the product label:\n\n• “75 mg Per Pump PROGESTERONE CREAM . . . Hormones \u002F Mood \u002F Sleep . . . Use 1 pump a day 1 to 3 minutes before a meal, or as recommended by your practitioner.”\n\nOn the product webpage:\n\n• “5 Benefits of Natural Progesterone Cream with ISO99: . . . Relieves Menopause Symptoms . . . promote bone density . . . Boosts Fertility . . . preventing miscarriage. . . . Treats Fibroid Tumors . . . Helps Endometriosis . . . Balance Hormones and Relieve PMS Symptoms . . . Relieves Inflammation”\n\nAnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP and AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump\n\nOn the product webpage:\n\n• “Natural Bio-Identical BIO-EST 2.5mg may help with menopause symptoms. . . . BENEFITS . . . Lower the risk of urinary tract infections (UTIs) . . . Strengthen bones and prevent osteoporosis”\n\n• “Natural Bio-Identical Bio-EST 5mg may help with menopause symptoms. . . . BENEFITS . . . Lower the risk of urinary tract infections (UTIs) . . . Strengthen bones and prevent osteoporosis”\n\nAnuMed™ 2.5 All Natural ESTRIOL CREAM and AnuMed™ 5.0 All Natural ESTRIOL CREAM\n\nOn the product webpage:\n\n• “Natural Bioidentical Estriol Cream 2.5 with Hyaluronic Acid . . . #1 Recommended Estriol Cream for Menopause Relief, Mood Swings, Hot Flashes, Breast soreness . . . Natural Hormone Balance”\n\n• “Natural Bioidentical Estriol Cream 5.0 with Hyaluronic Acid . . . #1 Recommended Estriol Cream for Menopause Relief, Mood Swings, Hot Flashes, Breast soreness . . . Natural Hormone Balance”\n\nAnuMed™ Bio-Identical DHEA 20 CREAM and AnuMed™ Bio-Identical DHEA 50 CREAM\n\nFrom your storefront on Amazon’s webpage https:\u002F\u002Fwww.amazon.com\u002FANUMED-Bioidentical-Dehydroepiandrosterone-Hyaluronic-Essential\u002Fdp\u002FB0BNHH4R8Q?th=1\n\n• “ANUMED – All Natural Bioidentical DHEA 20mg Cream . . . for Hormone Balance, Mood, Immune System . . . Natural Balancing of Hormone Levels, Promotes Mood, Immune System, Anti-Aging, Energy, Metabolism.”\n\nOn the product webpage:\n\n• “All Natural Bioidentical DHEA 50mg Cream (Dehydroepiandrosterone) + Hyaluronic Acid . . . Hormone Balance, Mood, Energy, Immune System . . . Natural Balancing of Hormone Levels. Promotes Mood, Immune System, Anti-Aging, Energy, Metabolism.”\n\n50,000 IU Vitamin D3+K2 CREAM\n\nOn the product label:\n\n• “With Hyaluronic Acid . . . May Increase Calcium Absorption . . . PSORIASIS & ECZEMA RELIEF . . . May help relieve skin flares caused by Psoriasis & Eczema. . . . Vitamin D is necessary for strong bones and teeth. . . . May Help muscle function & support immune system. . . . May help heal wounds faster such as fading bruising.”\n\nOn the product webpage:\n\n• “Vitamin D3 50,000 IU cream is our most potent vitamin-based solution created with the intent of replenishing the lowest vitamin deficiencies and relieving the symptoms of various conditions such as psoriasis and eczema in a minimal time frame. It can help with boosting immune system.”\n\nTravel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health Support\n\n• In the name of the product – “Parasite Cleanser”\n\nOn the product webpage:\n\n• “A proprietary blend of herbals along with zinc to help fight and eliminate parasites in the body”\n\n• “Wormwood kills adult parasites and especially pinworms.”\n\n• “Black Walnut which has anti-fungal and antibacterial properties and can kill intestinal parasites like roundworm and tapeworm. It helps to clean out any toxins and dangerous pathogens.”\n\n• “Clove Bud kills the parasite eggs that may be lingering in the intestinal tract along with worms . . . Thus, helps relieve indigestion and constipation problems. . . . These compounds provide potent antiseptic and anti-inflammatory benefits.”\n\n• “Fennel is helpful in reducing diarrhea if it is caused by bacterial infection because some components of the essential oil in fennel such as anetol and cineole have disinfectant and antibacterial properties.” • “Ginger is known as an anti-parasitic. Researchers show that it can inhibit a variety of worms and parasites..”\n\nVitamin C Booster - 2000mg\n\nOn the product webpage:\n\n• “Best protection support from cold, flu [influenza], virus [viral infection]”\n\n• “Zinc may help with wound healting [sic]”\n\n• “L-Lysine . . . Also, may help people with the herpes simplex virus (HSV) [viral infection] and diabetes.”\n\n• “Ultimate Defense from cold, Flu [influenza], Virus [viral infection], allergy”\n\nImmune Booster 90 Capsules\n\nOn the product webpage:\n\n• “Has Zinc for which . . . may help combat colds, upper respiratory infections and viruses [viral infection]. . . . This product not only boosts immune system to help make body strong in order to combat most viruses [viral infection] and infections”\n\nVegan Vitamin D3 K2 60ct Capsules\n\nOn the product webpage:\n\n• “Research studies have indicated that K2 intake can decrease bone loss among those with Osteoporosis.”\n\n• “Vitamin D deficiencies have been linked by researchers to . . . sleeping disorders.”\n\n• “Research has indicated that vitamin D, while in combination with other bodily properties, plays a pivotal role in fortifying the antibacterial potency of the essential immune cells.”\n\nB-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)\n\nOn the product webpage:\n\n• “Heart Disease: Research has found that B-12 in combination with B-6 and folic acid may help regulate and decrease the levels of homocysteine in the blood system, which are known to increase the chances of cardiovascular disease.”\n\n• “Dementia and Cognitive Abilities: . . . Research has indicated an association between low levels of B-12 and cognitive decline. As a result, the B-12 . . . solution may help support and replace the lack of the nutrient while improving cognitive function.”\n\n• “When the body has a deficiency of the vitamin, harmful bacteria begins to grow. A consistent intake of B-12 has demonstrated that it can help remove bad bacteria . . . and potentially prevent gastrointestinal disorders.”\n\n2oz Vitamin C Booster Drops\n\nOn the product webpage:\n\n• “Has been recommended to try and help ease cold and flu [influenza] symptoms.”\n\n• “Be prepared for fighting illness and germs.”\n\n2oz Anumed Zinc Drops\n\nOn the product webpage:\n\n• “Ultimate Defense from Cold, Flu [influenza], Virus [viral infection], Allergy”\n\nTurmeric Curcumin Drops 775mg with Black Pepper Extract\n\nOn the product webpage:\n\n• “Curcumin and other chemicals in turmeric might decrease swelling (inflammation). Because of this, turmeric might be beneficial for treating conditions that involve inflammation. Has been known to help with the reduction of inflammation, pain”\n\nYour “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ Bio-Identical DHEA 20 CREAM,” “AnuMed™ Bio-Identical DHEA 50 CREAM,” and “50,000 IU Vitamin D3+K2 CREAM,” “Travel Safe Drops: Advanced Intestinal Flora, Parasite Cleanser & Digestive Health Support,” “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin),” “2oz Vitamin C Booster Drops,” “2oz Anumed Zinc Drops,” and “Turmeric Curcumin Drops 775mg with Black Pepper Extract” products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here1, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products.2 Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nMisbranded Drugs\n\n“Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM” are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because the product labels and\u002For websites include statements that misleadingly suggest that the drug products are approved or endorsed by FDA in some way. For example, the website for Magnesium 50 mg Body Cream includes the image of a blue circle with the claim, “FDA * APPROVED * FACILITY.” Further, the product labels and\u002For websites for the other seven before-listed products include statements that these products are made or manufactured in an “FDA inspected and Certified Facility,” a “Certified FDA registered facility,” and\u002For a “FDA registered facility.” FDA’s regulations provide that “[r]egistration of an establishment or listing of a drug does not denote approval of the establishment, the drug, or other drugs of the establishment, nor does it mean that a product may be legally marketed” (21 CFR 207.77(a)). However, the general public is not likely to be familiar with the details of FDA’s regulations. The above assertions misleadingly suggest that the above-mentioned drug products are approved or endorsed by FDA in some way. Your “Magnesium 50 mg Body Cream,” “AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ Bio-Identical DHEA 50 CREAM” and “AnuMed™ Bio-Identical DHEA 20 CREAM” products are not the subjects of an FDA-approved application. Therefore, these products are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because their labeling is false or misleading. The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAdditionally, a drug is misbranded under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1) if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act, 21 U.S.C. 353(b)(1)(A), can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Vitamin C Booster - 2000mg,” “Immune Booster 90 Capsules,” “Vegan Vitamin D3 K2 60ct Capsules,” and “B-12 – 1000 and Vitamin B12 5000mcg Drops (Methylcobalamin)” are intended for prevention or treatment of one or more diseases that are not amenable to self-diagnosis, prevention, or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your before-noted products fail to bear adequate directions for their intended uses and, therefore, are misbranded under section 502(f)(1) of the Act, 21 U.S.C. 352(f)(1). The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nCGMP Violations\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou failed to perform adequate identity testing, including specific identity testing as appropriate, for each shipment of each lot of components, such as glycerin and ethyl alcohol (ethanol; alcohol), used in the manufacture of your drug products. During the inspection, you indicated that you were not aware testing was required and that you rely upon your supplier’s certificate of analysis (COA) for acceptance of incoming materials.\n\nAlcohol (Ethanol)\n\nIdentity testing for pharmaceutical alcohol (ethanol and isopropyl alcohol) includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of methanol. The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\nGlycerin\n\nIdentity testing for glycerin and certain other high-risk drug components3 include a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products. The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at risk for DEG or EG contamination, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn your response, you state that you are reviewing options for identity testing of raw materials. Your response is inadequate because you did not provide sufficient detail or evidence of corrective actions (e.g., assessing retain samples).\n\nWithout appropriate testing of components, you cannot ensure the quality and safety of your drug products.\n\nIn response to this letter, provide:\n\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\n• A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n• A commitment to provide test results for components used in the manufacture of your drug products, no later than 30 calendar days from the date of this letter, including testing retains for all lots of drug components at high-risk for DEG and EG contamination, and pharmaceutical alcohol for methanol contamination. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG, EG, and methanol.\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG, EG, or methanol contamination (including, but not limited to, glycerin and ethyl alcohol). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG, EG, or methanol including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\n2. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nLack of Process Validation\n\nYou failed to adequately validate your processes used to manufacture your drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality.\n\nIn your response, you state that your process validation procedure will be reviewed and personnel trained. However, your response is inadequate as you did not provide sufficient detail or evidence of corrective actions.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nInadequate Water System\n\nYour firm uses water as a component to manufacture your drug products. You failed to adequately qualify your purified water system. You also failed to show that your water system is adequately monitored to ensure it consistently produces water that meets appropriate microbial limits. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of ongoing state of control and suitability of water for use in manufacturing operations.\n\nIn your response, you state that your quality unit will begin conducting regular inspections to ensure the water system is adequate. However, your response is inadequate as you did not provide sufficient detail or evidence of corrective actions.\n\nPurified water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\n\nFurthermore, you manufacture drug products (including hormones) and non-pharmaceutical products (e.g., cosmetics) using shared equipment (e.g., (b)(4) tanks, (b)(4), and filling lines). In your response, you state that your cleaning validation procedure will be reviewed and revised to include the necessary cleaning validation studies. Adequate cleaning procedures are required as chemical and microbial residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\n\nIn response to this letter, provide:\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing PPQ for each of your marketed drug products.\n\n• Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\n• A comprehensive, independent assessment of your water system design, control, and maintenance.\n\n• A thorough remediation plan to assure you operate a suitable water system, including any redesign. Include a robust ongoing control, maintenance, and monitoring program to ensure the system consistently produces water adhering to Purified Water, USP monograph specifications and appropriate microbial limits.\n\n• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\n• Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\n• A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nYou failed to validate your non-compendial microbial methods used to test drug products and assure the methods were equivalent to or better than USP methods. For example, you use (b)(4) to analyze total count and yeast and mold in finished product. Additionally, you failed to follow the instructions for use and the investigator observed the use of expired (b)(4) test materials for finished product testing.\n\nIn your response, you indicate that you ceased use of the (b)(4) non-compendial tests. Your response is inadequate as you did not provide sufficient detail or evidence of corrective actions, including validation or verification of appropriate microbial methods for drug product testing by your contract laboratory or your internal laboratory, and to demonstrate that the methods used are equivalent to or better than USP methods. You also did not commit to conducting retrospective review of products tested using your non-compendial, non-validated tests.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision. Include specifications for drug products within expiration that are already distributed within the United States and specifications for future drug products.\n\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\n\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n\n• Chemical and microbial test method verification or validation reports and supporting data for internal and contracted testing of your components and drug products.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\n• An adequate system for retention of production, control, or distribution records associated for all batches of drug product (21 CFR 211.180(a)).\n\n• Batch production and control records include documentation of the accomplishment of each significant step in the manufacture and processing for each batch of drug product (21 CFR 211.188(b)).\n\n• Performance of periodic (i.e., at least annually) product reviews (21 CFR 211.180(e)).\n\n• Adequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. The QU must be accountable for implementing all the controls and reviewing the results of manufacture to ensure that product quality standards have been met. In smaller firms, it is recommended that another qualified individual, not involved in the production operation, conduct an additional, periodic review of QU activities. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nRepeat Observations at Facility\n\nIn a previous inspection ending December 13, 2017, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_________________\n\n1 Your AnuMed™ 25mg Per Pump PROGESTERONE CREAM,” “AnuMed™ 75mg Per Pump PROGESTERONE CREAM,” “AnuMed™ BIO-IDENTICAL BIO-EST 2.5mg PER PUMP,” “AnuMed™ BIO-IDENTICAL BIO-EST 5mg Per Pump,” “AnuMed™ 2.5 All Natural ESTRIOL CREAM,” “AnuMed™ 5.0 All Natural ESTRIOL CREAM, “AnuMed™ Bio-Identical DHEA 20 CREAM” and “AnuMed™ Bio-Identical DHEA 50 CREAM” drugs are hormone containing products that are deemed to be new drugs under a final determination issued under 21 CFR part 330, as published in the Federal Register on September 9, 1993 (see 58 FR 47610). There, the Agency has determined that any OTC drug product other than hydrocortisone that is labeled, represented, or promoted as a topically applied hormone-containing product for drug use are not generally recognized as safe and effective under section 201(p)(1) of the FD&C Act and that all such products are deemed to be new drugs and require an approved new drug application under section 505 of the FD&C Act to be lawfully marketed. 21 CFR 310.530.\n\nFurthermore, as an OTC combination psoriasis\u002Fskin protectant drug products, your “50,000 IU Vitamin D3+K2 CREAM” must conform to the conditions of use set forth in the Over-the-Counter Monograph M032: Drug Products for the Control of Dandruff, Seborrheic Dermatitis, and Psoriasis for Over-the-Counter Human Use (henceforth “M032”), encompassed under the final administrative order OTC000021 and the Over-the-Counter Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”) encompassed under the final administrative order OTC000005. However, your “50,000 IU Vitamin D3+K2 CREAM” does not conform to conditions specified in either M032 or M016 because its labeling has intended uses such as, “PSORIASIS & ECZEMA RELIEF” and “help heal wounds” that go beyond the general intended uses described in M032 and M016. Neither final order allows for such a combination of a psoriasis and a skin protectant. There is no basis under the FD&C Act under which these products would be legally marketed without an approved application.\n\n2 We recognize that the “Semaglutide Homeopathic Formula” labeling describes the products as being “homeopathic.”\n\nFirst, we note that under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\n\nIn addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States without the required FDA approval. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your product includes semaglutide, which is not listed in the HPUS; thus, this product falls outside the scope of products addressed in this guidance.\n\n3 Components with higher risk of DEG or EG contamination compared to other drug components.","AnuMed International, LLC","anumed-international-llc-674310-08202024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanumed-international-llc-674310-08202024","2026-10-26T08:07:56.270514+00:00","Warning Letter","Issued","2024-08-27","674310","Drugs","Julie R. Alcantar","2026-08-19T23:51:57.526+00:00","Via Email","2024-08-20",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":48,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},1872,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-09-12T13:00:00Z\">09\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-11T04:00:00Z\">09\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foclumed-llc-663525-09112023\">OcluMed LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>OcluMed LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>401 Commerce Drive Suite 201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Washington\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19034\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@oclumed.com\"> info@oclumed.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 11, 2023\u003C\u002Fp>\n\n\u003Cp>AgentOf LLC\u003Cbr>\n1280 Stillwater Drive\u003Cbr>\nMiami Beach, FL 33141\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 663525\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear OcluMed LLC:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Foclumed.com\u002F in July 2023. The FDA has observed that your website offers “OcluMed Nutritional\u002FLubricant Eye Drops” (hereinafter referred to as “OcluMed Eye Drops”) for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>Your unapproved “OcluMed Eye Drops” drug product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, your “OcluMed Eye Drops” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website https:\u002F\u002Foclumed.com\u002F that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On the webpage https:\u002F\u002Foclumed.com\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Now OcluMed is thinking outside the contact lenses aisle, with a scientifically proven formula designed with a potent blend of antioxidants to . . . prevent or improve cataracts . . . OcluMed is an effective solution for cataracts . . .”\u003C\u002Fli>\n\t\u003Cli>The webpage https:\u002F\u002Foclumed.com\u002F also contains evidence of intended use in the form of personal testimonials recommending or describing the use of your product for the cure, mitigation, treatment or prevention of disease. Examples of such testimonials include:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o “‘After taking the drops 3 times per day for almost 2 months…my surgeon stated that the cataract was down to a trace’”\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; o “‘I use the drops 1X a day in each eye. I went to my ophthalmologist and was concerned as I had not been to him in three years. I thought my cataracts would be worse. To my surprise, the cataracts were not worse, in fact, they had not progressed at all! Needless to say, I feel that my regime is working well and OcluMed drops are certainly a part of that.’”\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; o “‘I am very encouraged with my vision improvement with OcluMed eye drops. Prior to discovering these drops I was doomed to losing my vision, since I was diagnosed with macular degeneration and the beginning of cataracts . . . For the past 8 months I have religiously utilized a daily regimen of vitamins and OcluMed drops with extremely positive results.’”\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; o “‘I have been using Oclumed since at least 9\u002F29\u002F2013. It essentially helped to reverse the cataract condition in both of my eyes’”\u003C\u002Fp>\n\n\u003Cp>On the webpage https:\u002F\u002Foclumed.com\u002Fpages\u002Fabout-us:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“When cataracts cloud your vision, they stand between you and so many things you love to see and do. Proven over 80% effective at stabilizing and improving clarity when used over time, OcluMed is a powerful, natural approach to offsetting the effects of cataracts—delaying or eliminating the need for surgery. Its systems method of improving vision and treating senile cataracts is claimed in our pending patents and its efficacy and superiority is supported by our treatment results, which distinguishes our eye drop from other previous attempts to reduce oxidative damage in the eye that allows the eye to repair the cataract.”\u003C\u002Fli>\n\t\u003Cli>“Care for your eyes by making OcluMed part of your daily routine. Its patented system works on all aspects of eye health, from helping to slow or repair damage, to improving clarity and keeping cataracts surgery at bay.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your “OcluMed Eye Drops” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for “OcluMed Eye Drops.” Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to\u003Cbr>\nFDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nOcluMed LLC\n\n401 Commerce Drive Suite 201\n\nFort Washington, PA 19034\n\nUnited States\n\ninfo@oclumed.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nSeptember 11, 2023\n\nAgentOf LLC\n\n1280 Stillwater Drive\n\nMiami Beach, FL 33141\n\nRE: 663525\n\nDear OcluMed LLC:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Foclumed.com\u002F in July 2023. The FDA has observed that your website offers “OcluMed Nutritional\u002FLubricant Eye Drops” (hereinafter referred to as “OcluMed Eye Drops”) for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nYour unapproved “OcluMed Eye Drops” drug product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\n\nBased on a review of your website, your “OcluMed Eye Drops” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your website https:\u002F\u002Foclumed.com\u002F that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\n\nOn the webpage https:\u002F\u002Foclumed.com\u002F:\n\n“Now OcluMed is thinking outside the contact lenses aisle, with a scientifically proven formula designed with a potent blend of antioxidants to . . . prevent or improve cataracts . . . OcluMed is an effective solution for cataracts . . .”\n\nThe webpage https:\u002F\u002Foclumed.com\u002F also contains evidence of intended use in the form of personal testimonials recommending or describing the use of your product for the cure, mitigation, treatment or prevention of disease. Examples of such testimonials include:\n\no “‘After taking the drops 3 times per day for almost 2 months…my surgeon stated that the cataract was down to a trace’”\n\no “‘I use the drops 1X a day in each eye. I went to my ophthalmologist and was concerned as I had not been to him in three years. I thought my cataracts would be worse. To my surprise, the cataracts were not worse, in fact, they had not progressed at all! Needless to say, I feel that my regime is working well and OcluMed drops are certainly a part of that.’”\n\no “‘I am very encouraged with my vision improvement with OcluMed eye drops. Prior to discovering these drops I was doomed to losing my vision, since I was diagnosed with macular degeneration and the beginning of cataracts . . . For the past 8 months I have religiously utilized a daily regimen of vitamins and OcluMed drops with extremely positive results.’”\n\no “‘I have been using Oclumed since at least 9\u002F29\u002F2013. It essentially helped to reverse the cataract condition in both of my eyes’”\n\nOn the webpage https:\u002F\u002Foclumed.com\u002Fpages\u002Fabout-us:\n\n“When cataracts cloud your vision, they stand between you and so many things you love to see and do. Proven over 80% effective at stabilizing and improving clarity when used over time, OcluMed is a powerful, natural approach to offsetting the effects of cataracts—delaying or eliminating the need for surgery. Its systems method of improving vision and treating senile cataracts is claimed in our pending patents and its efficacy and superiority is supported by our treatment results, which distinguishes our eye drop from other previous attempts to reduce oxidative damage in the eye that allows the eye to repair the cataract.”\n\n“Care for your eyes by making OcluMed part of your daily routine. Its patented system works on all aspects of eye health, from helping to slow or repair damage, to improving clarity and keeping cataracts surgery at bay.”\n\nYour “OcluMed Eye Drops” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for “OcluMed Eye Drops.” Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to\n\nFDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration","OcluMed LLC","oclumed-llc-663525-09112023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foclumed-llc-663525-09112023","2026-10-26T08:09:37.038799+00:00","2023-09-12","663525","2026-08-20T00:42:06.987+00:00","2023-09-11",{"id":51,"raw":52,"subject":57,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":18,"fei_number":19,"letter_url":62,"updated_at":63,"action_type":22,"case_status":23,"posted_date":64,"marcs_cms_no":65,"product_type":66,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":67,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":68,"medical_device_id":19,"response_letter_date":19},1042,[53,54,55,11,56,13,13,13],"\u003Ctime datetime=\"2025-03-04T05:00:00Z\">03\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-25T05:00:00Z\">02\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftktx-numb-store-697051-02252025\">TKTX Numb Store\u003C\u002Fa>","Unapproved New Drug and Misbranded\u002FOTC\u003Cbr \u002F>\r\n\u003Cbr \u002F>\r\n","Unapproved New Drug and Misbranded\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>TKTX Numb Store\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:service@tktxnumbstore.com\"> service@tktxnumbstore.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 25, 2025\u003C\u002Fp>\u003Cp>RE: 697051\u003C\u002Fp>\u003Cp>Dear Sir\u002FMadam:\u003C\u002Fp>\u003Cp>This letter concerns your firm’s distribution of the drug products “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” indicated for use as external analgesics prior to sensitive cosmetic procedures. The United States Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address www.tktxnumbstore.com where the products are available for purchase in the United States without a prescription.\u003C\u002Fp>\u003Cp>“TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” are also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. 331(a) and (d).\u003C\u002Fp>\u003Cp>Your firm markets the above listed drug products as external analgesics, among other things,\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> to be used before and\u002For during various sensitive cosmetic procedures such as tattooing, piercing, laser cosmetic procedures, and others. These products are marketed without an approved application under section 505 of the FD&amp;C Act for indications that are not included in a final administrative order issued under section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Furthermore, these drug products include lidocaine concentrations that exceed what is permissible for over-the-counter (OTC) external analgesic drug products marketed without an approved application and\u002For include combinations of active ingredients that do not conform with the conditions of marketing in the external analgesics final administrative order issued under section 505G.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA has safety concerns about these external analgesic drug products, which include certain active ingredients at concentrations that exceed levels currently permitted in such nonprescription drug products, because they are intended to be used before or during certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA is aware that use of these products before and\u002For during a cosmetic procedure may not be supervised by trained health professionals. Without this supervision, large amounts of topical analgesics may be applied to a person’s skin. FDA has specifically warned in multiple public health advisories\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and a recent news release\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when the skin is covered after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the product labeling, including the website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub]”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“TOPICAL ANESTHETIC CREAM” [from the product website]\u003C\u002Fp>\u003Cp>“\u003Cstrong>DRUG FACTS…Active Ingredient\u003C\u002Fstrong>…Lidocaine 5%, Prilocaine, Epinephrine…Local Anesthetic…\u003Cstrong>Uses:\u003C\u002Fstrong> For the temporary relief of ■ TATTOOING ■ PIERCING ■ PERMANENT MAKEUP ■ LASER TREATMENTS ■ WAXING ■ MESO PROCEDURES” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX plus 200% More Volume”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“\u003Cstrong>Active ingredients\u003C\u002Fstrong> - Lido5%,Prilo, Epine…\u003Cstrong>Uses\u003C\u002Fstrong> – For the temporary relief the discomfort of ∙ TATTOOING ∙ PIERCING ∙ PERMANENT MAKEUP ∙ LASER TREATMENTS ∙ WAXING ∙ MESO PROCEDURES” [from the product website]\u003C\u002Fp>\u003Cp>“…Best for minor cuts, minor scrapes, minor burns, insect bites, anorectal disorder” [from the product website]\u003C\u002Fp>\u003Cp>“\u003Cstrong>Helps Reduce Inflammation\u003C\u002Fstrong> - Enriched with Vitamin E, your TKTX topical helps relieve swelling. your TKTX topical helps relieve swelling…”[from the product website]\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX RAPID NUMB &amp; LONG LASTING”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“FAST PAIN RELIEF” [from the product website]\u003C\u002Fp>\u003Cp>“Topical Anesthetic Cream” [from the product website]\u003C\u002Fp>\u003Cp>“5% LIDO TOPICAL CREAM MAXIMUM STRENGTH…\u003Cstrong>APPLY\u003C\u002Fstrong>-Great for tattoos, tattoo removals, piercings and laser waxing” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003Cbr>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003Cbr>Under section 505G of the FD&amp;C Act, 21 U.S.C. 355h, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesic monograph”).\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” do not conform to the conditions of use specified in the external analgesic monograph for the reasons described below.\u003C\u002Fp>\u003Cp>The combinations and\u002For concentrations of the active ingredients identified in the product labeling for “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” do not conform to the conditions of use set forth in M017. Specifically, lidocaine, the active ingredient in all of these products is at a concentration of 5%. These concentrations are above the 0.5% to 4% concentration range of lidocaine permitted by M017.\u003C\u002Fp>\u003Cp>Additionally, these drug products also include lidocaine in combination with other active ingredients that are not permitted by M017. Specifically, “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub]” and “TKTX plus 200% More Volume,” contain lidocaine 5%, prilocaine, and epinephrine as active ingredients. Neither epinephrine nor prilocaine are permitted as active ingredients by M017. Moreover, prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\u003C\u002Fp>\u003Cp>Furthermore, the labeling for TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” include indications that are not consistent with the indications for external analgesic drug products. Claims from the product labeling described above related to tattooing, piercing, and laser cosmetic procedures go beyond merely describing the general intended uses for an external analgesic drug product. Indications related to tattooing, piercing, and laser cosmetic procedures are not included in M017 or any other final administrative order in accordance with section 505G.\u003C\u002Fp>\u003Cp>We note that “TKTX plus 200% More Volume” also appears to be indicated to relieve pain associated with anorectal disorders. OTC anorectal drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use. Indications related to tattooing and piercing are not included in M015. As stated in the introduction to this letter, we have safety concerns related to the use of these products for these indications due to the potential for greater absorption of the active ingredients through irritated or broken skin.\u003C\u002Fp>\u003Cp>Thus, “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without and approved application. Because there are no approved applications in effect for these products, they are unapproved new drugs. The introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Further, “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with these products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that “TKTX plus 200% More Volume” also appears to be indicated to relieve pain associated with anorectal disorders. OTC anorectal drug products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use. This product does not conform to the conditions set forth in this monograph. “TKTX plus 200% More Volume” is labeled as both an external analgesic and anorectal drug product. This product cannot meet the requirements of both M017 and M015 with lidocaine or lidocaine HCl as an active ingredient at or above a concentration of 5% nor with a combination of active ingredients of lidocaine, prilocaine, and epinephrine. Moreover, prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR part 330 prior to enactment of the CARES Act. In the case of OTC external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Refer to FDA public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>Refer to the March 26, 2024 news release titled, “FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Ffda-warns-consumers-avoid-certain-topical-pain-relief-products-due-potential-dangerous-health.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions as set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB &amp; LONG LASTING” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nTKTX Numb Store\n\nUnited States\n\nservice@tktxnumbstore.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 25, 2025\nRE: 697051\nDear Sir\u002FMadam:\nThis letter concerns your firm’s distribution of the drug products “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” indicated for use as external analgesics prior to sensitive cosmetic procedures. The United States Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address www.tktxnumbstore.com where the products are available for purchase in the United States without a prescription.\n“TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” are also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d).\nYour firm markets the above listed drug products as external analgesics, among other things,1 to be used before and\u002For during various sensitive cosmetic procedures such as tattooing, piercing, laser cosmetic procedures, and others. These products are marketed without an approved application under section 505 of the FD&C Act for indications that are not included in a final administrative order issued under section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Furthermore, these drug products include lidocaine concentrations that exceed what is permissible for over-the-counter (OTC) external analgesic drug products marketed without an approved application and\u002For include combinations of active ingredients that do not conform with the conditions of marketing in the external analgesics final administrative order issued under section 505G.2\nFDA has safety concerns about these external analgesic drug products, which include certain active ingredients at concentrations that exceed levels currently permitted in such nonprescription drug products, because they are intended to be used before or during certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA is aware that use of these products before and\u002For during a cosmetic procedure may not be supervised by trained health professionals. Without this supervision, large amounts of topical analgesics may be applied to a person’s skin. FDA has specifically warned in multiple public health advisories3 and a recent news release4 about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when the skin is covered after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\nUnapproved New Drug and Misbranded Drug Violations\n“TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the product labeling, including the website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not limited to, the following:\n“TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub]”\n“TOPICAL ANESTHETIC CREAM” [from the product website]\n“DRUG FACTS…Active Ingredient…Lidocaine 5%, Prilocaine, Epinephrine…Local Anesthetic…Uses: For the temporary relief of ■ TATTOOING ■ PIERCING ■ PERMANENT MAKEUP ■ LASER TREATMENTS ■ WAXING ■ MESO PROCEDURES” [from the product website]\n“TKTX plus 200% More Volume”\n“Active ingredients - Lido5%,Prilo, Epine…Uses – For the temporary relief the discomfort of ∙ TATTOOING ∙ PIERCING ∙ PERMANENT MAKEUP ∙ LASER TREATMENTS ∙ WAXING ∙ MESO PROCEDURES” [from the product website]\n“…Best for minor cuts, minor scrapes, minor burns, insect bites, anorectal disorder” [from the product website]\n“Helps Reduce Inflammation - Enriched with Vitamin E, your TKTX topical helps relieve swelling. your TKTX topical helps relieve swelling…”[from the product website]\n“TKTX RAPID NUMB & LONG LASTING”\n“FAST PAIN RELIEF” [from the product website]\n“Topical Anesthetic Cream” [from the product website]\n“5% LIDO TOPICAL CREAM MAXIMUM STRENGTH…APPLY-Great for tattoos, tattoo removals, piercings and laser waxing” [from the product website]\nUnapproved New Drug Violations\nBased on the above labeling evidence “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, 21 U.S.C. 355h, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesic monograph”).5 However, “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” do not conform to the conditions of use specified in the external analgesic monograph for the reasons described below.\nThe combinations and\u002For concentrations of the active ingredients identified in the product labeling for “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” do not conform to the conditions of use set forth in M017. Specifically, lidocaine, the active ingredient in all of these products is at a concentration of 5%. These concentrations are above the 0.5% to 4% concentration range of lidocaine permitted by M017.\nAdditionally, these drug products also include lidocaine in combination with other active ingredients that are not permitted by M017. Specifically, “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub]” and “TKTX plus 200% More Volume,” contain lidocaine 5%, prilocaine, and epinephrine as active ingredients. Neither epinephrine nor prilocaine are permitted as active ingredients by M017. Moreover, prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\nFurthermore, the labeling for TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” include indications that are not consistent with the indications for external analgesic drug products. Claims from the product labeling described above related to tattooing, piercing, and laser cosmetic procedures go beyond merely describing the general intended uses for an external analgesic drug product. Indications related to tattooing, piercing, and laser cosmetic procedures are not included in M017 or any other final administrative order in accordance with section 505G.\nWe note that “TKTX plus 200% More Volume” also appears to be indicated to relieve pain associated with anorectal disorders. OTC anorectal drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use. Indications related to tattooing and piercing are not included in M015. As stated in the introduction to this letter, we have safety concerns related to the use of these products for these indications due to the potential for greater absorption of the active ingredients through irritated or broken skin.\nThus, “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.6 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without and approved application. Because there are no approved applications in effect for these products, they are unapproved new drugs. The introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nMisbranded Drug Violations\nFurther, “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with these products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n______________________\n1 We note that “TKTX plus 200% More Volume” also appears to be indicated to relieve pain associated with anorectal disorders. OTC anorectal drug products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use. This product does not conform to the conditions set forth in this monograph. “TKTX plus 200% More Volume” is labeled as both an external analgesic and anorectal drug product. This product cannot meet the requirements of both M017 and M015 with lidocaine or lidocaine HCl as an active ingredient at or above a concentration of 5% nor with a combination of active ingredients of lidocaine, prilocaine, and epinephrine. Moreover, prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\n2 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR part 330 prior to enactment of the CARES Act. In the case of OTC external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\n3 Refer to FDA public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\n4 Refer to the March 26, 2024 news release titled, “FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Ffda-warns-consumers-avoid-certain-topical-pain-relief-products-due-potential-dangerous-health.\n5 M017 reflects the conditions as set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\n6 FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination “TKTX TOPICAL ANESTHETIC CREAM 5% Lidocaine [TKTX Tub],” “TKTX plus 200% More Volume,” and “TKTX RAPID NUMB & LONG LASTING” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.","TKTX Numb Store","tktx-numb-store-697051-02252025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftktx-numb-store-697051-02252025","2026-10-26T08:10:12.990553+00:00","2025-03-04","697051","Drugs Over-the-Counter Drugs","2026-08-19T17:00:09.278+00:00","2025-02-25",{"id":70,"raw":71,"subject":75,"body_html":76,"body_text":77,"firm_name":78,"letter_id":79,"created_at":43,"fei_number":19,"letter_url":80,"updated_at":81,"action_type":22,"case_status":23,"posted_date":82,"marcs_cms_no":83,"product_type":84,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":85,"delivery_method":19,"recipient_title":19,"reference_number":86,"action_taken_date":87,"medical_device_id":19,"response_letter_date":19},1551,[72,73,74,37,75,13,13,13],"\u003Ctime datetime=\"2024-03-26T04:00:00Z\">03\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-25T04:00:00Z\">03\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftattoo-numbing-cream-co-672467-03252024\">Tattoo Numbing Cream Co. \u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>3028008119\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Cosmetics\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Tattoo Numbing Cream Co. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@tattoonumbingcream.com.au\"> info@tattoonumbingcream.com.au\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@tattoonumbingcream.com\"> info@tattoonumbingcream.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 25, 2024\u003Cbr>\n\u003Cbr>\nRE: 3028008119\u003C\u002Fp>\n\n\u003Cp>Dear Sir\u002FMadam:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of the drug products, SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY for use as external analgesics prior to sensitive cosmetic procedures. The United States Food and Drug Administration (FDA) reviewed your website in November 2023 at the Internet address https:\u002F\u002Ftattoonumbingcream.com\u002F where these products are available for purchase.\u003C\u002Fp>\n\n\u003Cp>Based on our review, SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). These violations are described in more detail below. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>Your firm markets the above listed drug products as external analgesics to be used before, during, and\u002For after various sensitive cosmetic procedures such as tattooing. These products are marketed without an approved application under section 505 of the FD&amp;C Act for indications that are not included in a final administrative order issued under section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Furthermore, your drug products include lidocaine concentrations that exceed what is permissible for over-the-counter (OTC) external analgesic drug products marketed without an approved application and\u002For include combinations of active ingredients that do not conform with the conditions of marketing in the external analgesics final administrative order issued under section 505G.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>FDA has safety concerns about your external analgesic drug products, which include certain active ingredients at concentrations that exceed levels currently permitted in such nonprescription drug products, because they are intended to be used before or during certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA has specifically warned in multiple public health advisories\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when the skin is covered after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as external analgesic drug products for tattooing procedures.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the product labeling, including your product website https:\u002F\u002Ftattoonumbingcream.com\u002F and your social media accounts on Facebook and Instagram, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>&nbsp; &nbsp; SIGNATURE TATTOO NUMBING CREAM:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>&nbsp; &nbsp;&nbsp;\u003C\u002Fstrong>“Designed by Tattoo Artists in Australia. Used for numbing local area prior to tattooing…Join our pain free tattoo revolution!...For numbing a localized topical area to ease pain during tattoo procedures.” [from your product label]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; &nbsp;“Our Signature Tattoo Numbing Cream is your secret weapon for your next tattoo appointment. Imagine getting tattooed pain free. That’s totally possible using this cream…Using this numbing cream for tattoos you can: Numb an area for up to 3 hours (some people say it works for longer).” [from your product website https:\u002F\u002Fwww.tattoonumbingcream.com\u002Fproducts\u002Fsignature- tattoo-numbing-cream]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “\u003Cstrong>Steps for use:\u003C\u002Fstrong> …3. Cover tightly with cling film or our patented Numbing Garments”…“Your skin should remain numb for 3-4 hours, on average, once cream is removed depending on your skin type and location on the body. If using on broken skin, although our Miracle Numb Spray is much more suitable for this, only leave on broken skin for a maximum of 20 minutes at a time.” [from your product website https:\u002F\u002Fwww.tattoonumbingcream.com\u002Fpages\u002Fdirections-of-use]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “You mean to tell me I can get tatted up and not feel a thing? Order it right now! Tattoo Numbing Cream” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002Fphoto\u002F?fbid=670068798487576&amp;set=pb.100064533858343.- 2207520000]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “#NewGearsForPainFreeTattoo.” [from your Instagram social media account https:\u002F\u002Fwww.facebook.com\u002Ftattoonumbingcreamco\u002Fphotos\u002Fpb.100064533858343.- 2207520000\u002F1940516569621408\u002F?type=3]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp;“Numb Dad for Fathers Day. Heres 20% off your order so you can gift dad a peaceful, pain-free tattoo session this fathers day.” [from your Facebook social media account https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCwoNinPOoFD\u002F]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>&nbsp; &nbsp; MIRACLE NUMB SPRAY:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “Whether you forgot to use our Signature Tattoo Numbing Cream or it’s starting to wear off, Miracle Numb Spray is perfect to apply mid-session (even on broken skin). Be sure to get a bottle so you don’t tap out and can finish your tattoo.” [from your product website https:\u002F\u002Fwww.tattoonumbingcream.com\u002Fproducts\u002Fmiracle-numb-spray]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “This product is designed for use during a tattoo, after the skin has been broken (the tattoo has started) although most people typically achieve a level of numbness if sprayed on unbroken skin 10-20 minutes before being tattooed.”…“\u003Cstrong>Steps for use:\u003C\u002Fstrong>…2. Spray sparingly on broken skin throughout tattoo session. 3. Allow to absorb for 5-10 minutes. 4. Re-apply as needed”…“ The skin will typically remain numb for 1-2 hours. Only administer 1-2 sprays at a time on the area that is currently being tattooed, then move on to other areas as needed throughout the session.” [from your product website https:\u002F\u002Fwww.tattoonumbingcream.com\u002Fpages\u002Fdirections-of-use]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; “#NewGearsForPainFreeTattoo.” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002Ftattoonumbingcreamco\u002Fphotos\u002Fpb.100064533858343.- 2207520000\u002F1940516569621408\u002F?type=3]\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp;“Numb Dad for Fathers Day. Here’s 20% off your order so you can gift dad a peaceful, pain- free tattoo session this fathers day.” [from your Instagram social media account https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCwoNinPOoFD\u002F]\u003C\u002Fp>\n\n\u003Cp>Your SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY drug products are external analgesic drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&amp;C Act, 21 U.S.C. 355h(a)(1), certain nonprescription drugs marketed without an approved application may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesic monograph”).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, your products do not conform to the conditions of use specified in the external analgesic monograph for the reasons described below.\u003C\u002Fp>\n\n\u003Cp>The labeled combinations and\u002For concentrations for the active ingredients identified in product labels for SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY do not conform to the conditions of use set forth in M017. Specifically, lidocaine, an active ingredient labeled to be in both of these products, is listed as lidocaine 5%. This concentration is above the 0.5% to 4% concentration range of lidocaine permitted by M017. In addition, these drug products also include a combination of lidocaine and other active ingredients that are not permitted by M017. Specifically, SIGNATURE TATTOO NUMBING CREAM identifies 5% prilocaine and 1% epinephrine as additional active ingredients, and MIRACLE NUMB SPRAY identifies 4% prilocaine, 1% epinephrine, propylamine, glycerol, and purified water all as additional active ingredients. However, the external analgesic monograph does not permit a combination of more than one “-caine” type active ingredient in a single drug product, and epinephrine, propylamine, glycerol, and purified water are not permitted as active ingredients by M017.\u003C\u002Fp>\n\n\u003Cp>Furthermore, labeling for SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY include indications that are not consistent with the indications for external analgesic drug products. Claims on your SIGNATURE TATTOO NUMBING CREAM product such as “Our Signature Tattoo Numbing Cream is your secret weapon for your next tattoo appointment” and statements on your MIRACLE NUMB SPRAY product such as “[w]hether you forgot to use our Signature Tattoo Numbing Cream or it’s starting to wear off, Miracle Numb Spray is perfect to apply mid-session (even on broken skin). Be sure to get a bottle so you don’t tap out and can finish your tattoo,” go beyond merely describing the general intended uses for an external analgesic drug product. Indications related to tattooing are not included in M017, or any other final administrative order in accordance with section 505G. As stated in the introduction to this letter, we have safety concerns related to the use of these products for these indications due to the potential for greater absorption of the active ingredients through irritated or broken skin.\u003C\u002Fp>\n\n\u003Cp>Thus, SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY do not comply with the external analgesic monograph described above, nor are they otherwise marketed in accordance with section 505G.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subjects of applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR part 330 prior to enactment of the CARES Act. In the case of OTC external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Refer to FDA public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Reference #:\n\n3028008119\n\nProduct:\n\nCosmetics\nDrugs\n\nRecipient:\n\nTattoo Numbing Cream Co.\n\nUnited Kingdom\n\ninfo@tattoonumbingcream.com.au\n\ninfo@tattoonumbingcream.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nMarch 25, 2024\n\nRE: 3028008119\n\nDear Sir\u002FMadam:\n\nThis letter concerns your firm’s distribution of the drug products, SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY for use as external analgesics prior to sensitive cosmetic procedures. The United States Food and Drug Administration (FDA) reviewed your website in November 2023 at the Internet address https:\u002F\u002Ftattoonumbingcream.com\u002F where these products are available for purchase.\n\nBased on our review, SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). These violations are described in more detail below. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d).\n\nYour firm markets the above listed drug products as external analgesics to be used before, during, and\u002For after various sensitive cosmetic procedures such as tattooing. These products are marketed without an approved application under section 505 of the FD&C Act for indications that are not included in a final administrative order issued under section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Furthermore, your drug products include lidocaine concentrations that exceed what is permissible for over-the-counter (OTC) external analgesic drug products marketed without an approved application and\u002For include combinations of active ingredients that do not conform with the conditions of marketing in the external analgesics final administrative order issued under section 505G.1\n\nFDA has safety concerns about your external analgesic drug products, which include certain active ingredients at concentrations that exceed levels currently permitted in such nonprescription drug products, because they are intended to be used before or during certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA has specifically warned in multiple public health advisories2 about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when the skin is covered after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\n\nUnapproved New Drug Violations\n\nSIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body. Specifically, these products are intended for use as external analgesic drug products for tattooing procedures.\n\nExamples of claims observed on the product labeling, including your product website https:\u002F\u002Ftattoonumbingcream.com\u002F and your social media accounts on Facebook and Instagram, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but are not limited to, the following:\n\nSIGNATURE TATTOO NUMBING CREAM:\n\n“Designed by Tattoo Artists in Australia. Used for numbing local area prior to tattooing…Join our pain free tattoo revolution!...For numbing a localized topical area to ease pain during tattoo procedures.” [from your product label]\n\n“Our Signature Tattoo Numbing Cream is your secret weapon for your next tattoo appointment. Imagine getting tattooed pain free. That’s totally possible using this cream…Using this numbing cream for tattoos you can: Numb an area for up to 3 hours (some people say it works for longer).” [from your product website https:\u002F\u002Fwww.tattoonumbingcream.com\u002Fproducts\u002Fsignature- tattoo-numbing-cream]\n\n“Steps for use: …3. Cover tightly with cling film or our patented Numbing Garments”…“Your skin should remain numb for 3-4 hours, on average, once cream is removed depending on your skin type and location on the body. If using on broken skin, although our Miracle Numb Spray is much more suitable for this, only leave on broken skin for a maximum of 20 minutes at a time.” [from your product website https:\u002F\u002Fwww.tattoonumbingcream.com\u002Fpages\u002Fdirections-of-use]\n\n“You mean to tell me I can get tatted up and not feel a thing? Order it right now! Tattoo Numbing Cream” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002Fphoto\u002F?fbid=670068798487576&set=pb.100064533858343.- 2207520000]\n\n“#NewGearsForPainFreeTattoo.” [from your Instagram social media account https:\u002F\u002Fwww.facebook.com\u002Ftattoonumbingcreamco\u002Fphotos\u002Fpb.100064533858343.- 2207520000\u002F1940516569621408\u002F?type=3]\n\n“Numb Dad for Fathers Day. Heres 20% off your order so you can gift dad a peaceful, pain-free tattoo session this fathers day.” [from your Facebook social media account https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCwoNinPOoFD\u002F]\n\nMIRACLE NUMB SPRAY:\n\n“Whether you forgot to use our Signature Tattoo Numbing Cream or it’s starting to wear off, Miracle Numb Spray is perfect to apply mid-session (even on broken skin). Be sure to get a bottle so you don’t tap out and can finish your tattoo.” [from your product website https:\u002F\u002Fwww.tattoonumbingcream.com\u002Fproducts\u002Fmiracle-numb-spray]\n\n“This product is designed for use during a tattoo, after the skin has been broken (the tattoo has started) although most people typically achieve a level of numbness if sprayed on unbroken skin 10-20 minutes before being tattooed.”…“Steps for use:…2. Spray sparingly on broken skin throughout tattoo session. 3. Allow to absorb for 5-10 minutes. 4. Re-apply as needed”…“ The skin will typically remain numb for 1-2 hours. Only administer 1-2 sprays at a time on the area that is currently being tattooed, then move on to other areas as needed throughout the session.” [from your product website https:\u002F\u002Fwww.tattoonumbingcream.com\u002Fpages\u002Fdirections-of-use]\n\n“#NewGearsForPainFreeTattoo.” [from your Facebook social media account https:\u002F\u002Fwww.facebook.com\u002Ftattoonumbingcreamco\u002Fphotos\u002Fpb.100064533858343.- 2207520000\u002F1940516569621408\u002F?type=3]\n\n“Numb Dad for Fathers Day. Here’s 20% off your order so you can gift dad a peaceful, pain- free tattoo session this fathers day.” [from your Instagram social media account https:\u002F\u002Fwww.instagram.com\u002Fp\u002FCwoNinPOoFD\u002F]\n\nYour SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY drug products are external analgesic drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Under section 505G(a)(1) of the FD&C Act, 21 U.S.C. 355h(a)(1), certain nonprescription drugs marketed without an approved application may be legally marketed if they meet applicable requirements. With respect to OTC external analgesic drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesic monograph”).3 However, your products do not conform to the conditions of use specified in the external analgesic monograph for the reasons described below.\n\nThe labeled combinations and\u002For concentrations for the active ingredients identified in product labels for SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY do not conform to the conditions of use set forth in M017. Specifically, lidocaine, an active ingredient labeled to be in both of these products, is listed as lidocaine 5%. This concentration is above the 0.5% to 4% concentration range of lidocaine permitted by M017. In addition, these drug products also include a combination of lidocaine and other active ingredients that are not permitted by M017. Specifically, SIGNATURE TATTOO NUMBING CREAM identifies 5% prilocaine and 1% epinephrine as additional active ingredients, and MIRACLE NUMB SPRAY identifies 4% prilocaine, 1% epinephrine, propylamine, glycerol, and purified water all as additional active ingredients. However, the external analgesic monograph does not permit a combination of more than one “-caine” type active ingredient in a single drug product, and epinephrine, propylamine, glycerol, and purified water are not permitted as active ingredients by M017.\n\nFurthermore, labeling for SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY include indications that are not consistent with the indications for external analgesic drug products. Claims on your SIGNATURE TATTOO NUMBING CREAM product such as “Our Signature Tattoo Numbing Cream is your secret weapon for your next tattoo appointment” and statements on your MIRACLE NUMB SPRAY product such as “[w]hether you forgot to use our Signature Tattoo Numbing Cream or it’s starting to wear off, Miracle Numb Spray is perfect to apply mid-session (even on broken skin). Be sure to get a bottle so you don’t tap out and can finish your tattoo,” go beyond merely describing the general intended uses for an external analgesic drug product. Indications related to tattooing are not included in M017, or any other final administrative order in accordance with section 505G. As stated in the introduction to this letter, we have safety concerns related to the use of these products for these indications due to the potential for greater absorption of the active ingredients through irritated or broken skin.\n\nThus, SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY do not comply with the external analgesic monograph described above, nor are they otherwise marketed in accordance with section 505G.4 Therefore, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMisbranding Violations\n\nSIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because they are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subjects of applications approved under section 505 of the FD&C Act, 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n_________________________\n\n1 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR part 330 prior to enactment of the CARES Act. In the case of OTC external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.)\n\n2 Refer to FDA public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\n\n3 See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n\n4 FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that SIGNATURE TATTOO NUMBING CREAM and MIRACLE NUMB SPRAY are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.","Tattoo Numbing Cream Co.","tattoo-numbing-cream-co-672467-03252024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftattoo-numbing-cream-co-672467-03252024","2026-10-26T08:10:10.027249+00:00","2024-03-26","672467","CosmeticsDrugs","2026-08-20T00:13:37.741+00:00","3028008119","2024-03-25",{"id":89,"raw":90,"subject":92,"body_html":93,"body_text":94,"firm_name":95,"letter_id":96,"created_at":18,"fei_number":19,"letter_url":97,"updated_at":98,"action_type":22,"case_status":23,"posted_date":64,"marcs_cms_no":99,"product_type":66,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":100,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":68,"medical_device_id":19,"response_letter_date":19},1044,[53,54,91,11,92,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftktx-numbing-cream-usa-702106-02252025\">TKTX Numbing Cream USA\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>TKTX Numbing Cream USA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7831 20th St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Westminster\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92683\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:contact@tktxnumbingcreamusa.com\"> contact@tktxnumbingcreamusa.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 25, 2025\u003C\u002Fp>\u003Cp>RE: 702106\u003C\u002Fp>\u003Cp>Dear Sir\u002FMadam:\u003C\u002Fp>\u003Cp>This letter concerns your firm’s distribution of the drug products, “Yellow TKTX Numbing Cream 40%,” “White TKTX Numbing Cream 40%,” “Gold TKTX Numbing Cream 40%,” and “Black TKTX Numbing Cream 40%” (hereinafter collectively referred to as “TKTX Numbing Creams”), for use as external analgesics prior to sensitive cosmetic procedures. The United States Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address www.tktxnumbingcreamusa.com, where your products are available for purchase in the United States without a prescription.\u003C\u002Fp>\u003Cp>“TKTX Numbing Creams” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). “TKTX Numbing Creams” are also misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. 331(a) and (d).\u003C\u002Fp>\u003Cp>Your firm markets the above listed drug products as external analgesics to be used before and\u002For during various sensitive cosmetic procedures such as tattooing, laser cosmetic procedures, microblading, and others. These products are marketed without an approved application under section 505 of the FD&amp;C Act for indications that are not included in a final administrative order issued under section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Furthermore, these drug products include lidocaine concentrations that exceed what is permissible for over-the-counter (OTC) external analgesic drug products marketed without an approved application and\u002For include a combination of active ingredients that does not conform to the conditions of marketing in the external analgesics final administrative order issued under section 505G.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA has safety concerns about your external analgesic drug products, which include certain active ingredients at concentrations that exceed levels currently permitted in such nonprescription drug products, because they are intended to be used before or during certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA is aware that use of these products before and\u002For during a cosmetic procedure may not be supervised by trained health professionals. Without this supervision, large amounts of topical analgesics may be applied to a person’s skin. FDA has specifically warned in multiple public health advisories\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and a recent news release\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when the skin is covered after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“TKTX Numbing Creams” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “TKTX Numbing Creams” products’ labeling, including the website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>“Yellow TKTX Numbing Cream 40%”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Yellow TKTX Numbing Cream 40% takes the edge off tattoos, piercings, and cosmetic treatments so you can focus on the results you love.” [from the product website]\u003C\u002Fp>\u003Cp>“Are you ready to experience a tattoo session that’s more about the art and less about the ouch? At TKTX Numbing Cream USA, we introduce Yellow TKTX Numbing Cream, your go-to solution for a smooth and comfortable tattooing journey.” [from the product website]\u003C\u002Fp>\u003Cp>“Yellow TKTX Numbing Cream is crafted with high-quality ingredients, including 5% lidocaine, a proven anesthetic, ensuring a safe and effective numbing experience.” [from the product website]\u003C\u002Fp>\u003Cp>“Simply cleanse the area, apply a generous layer, and cover with plastic wrap for 40-60 minutes, and you’re all set for a comfortable tattoo session.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cstrong>“Can I use it for other procedures besides tattoos?\u003C\u002Fstrong> While primarily designed for tattoos, Yellow TKTX can also be used for other minor procedures such as piercings and laser hair removal.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cu>“White TKTX Numbing Cream 40%”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“White TKTX Numbing Cream 40% takes the edge off tattoos, piercings, and cosmetic treatments so you can focus on the results you love.” [from the product website]\u003C\u002Fp>\u003Cp>“Ready to embrace the artistry of tattoos without the sting? At TKTX Numbing Cream USA, we present White TKTX Numbing Cream, your ultimate solution for a comfortable and enjoyable tattoo session.” [from the product website]\u003C\u002Fp>\u003Cp>“White TKTX Numbing Cream is formulated with high-quality ingredients, including 5% lidocaine, a proven anesthetic.” [from the product website]\u003C\u002Fp>\u003Cp>“Simply cleanse the area, apply a thick layer, and cover with plastic wrap for 40-60 minutes, and you’re ready for a pain-free tattoo session.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cstrong>“Can I use it for other procedures besides tattoos?\u003C\u002Fstrong> While primarily designed for tattoos, White TKTX Numbing Cream can also be used for other minor procedures like piercings and laser hair removal.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cu>“Gold TKTX Numbing Cream 40%”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Gold TKTX Numbing Cream 40% takes the edge off tattoos, piercings, and cosmetic treatments so you can focus on the results you love.” [from the product website]\u003C\u002Fp>\u003Cp>“Are you ready to indulge in a luxurious tattoo experience where pain is a distant memory? At TKTX Numbing Cream USA, we present Gold TKTX Numbing Cream…This premium topical anesthetic is meticulously formulated to provide deep and lasting numbing, ensuring a comfortable and enjoyable tattoo session that feels nothing short of extraordinary.” [from the product website]\u003C\u002Fp>\u003Cp>“Gold TKTX Numbing Cream is crafted with the finest ingredients, including a powerful blend of 5% lidocaine and prilocaine, ensuring a safe and effective numbing experience.” [from the product website]\u003C\u002Fp>\u003Cp>“Simply cleanse the area, apply a generous layer, cover with plastic wrap for 40-60 minutes, and you’re all set for a comfortable tattoo session.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cstrong>“Can I use it for other procedures besides tattoos?\u003C\u002Fstrong> While primarily designed for tattoos, Gold TKTX Numbing Cream can also be used for other minor procedures such as piercings and laser hair removal.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cu>“Black TKTX Numbing Cream 40%”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“Black TKTX Numbing Cream 40% takes the edge off tattoos, piercings, and cosmetic treatments so you can focus on the results you love.” [from the product website]\u003C\u002Fp>\u003Cp>“Are you ready to transform your tattoo experience from daunting to delightful? At TKTX Numbing Cream USA, we present Black TKTX Numbing Cream….” [from the product website]\u003C\u002Fp>\u003Cp>“Black TKTX Numbing Cream is crafted with high-quality ingredients, including 5% lidocaine and prilocaine, ensuring a safe and effective numbing experience.” [from the product website]\u003C\u002Fp>\u003Cp>“Simply cleanse the area, apply a generous layer, and cover with plastic wrap for 40-60 minutes, and you’re ready for a virtually pain-free tattoo session.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cstrong>“Can I use it for other procedures besides tattoos?\u003C\u002Fstrong> While primarily intended for tattoos, Black TKTX can also be used for other minor procedures such as piercings and laser hair removal.” [from the product website]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence “TKTX Numbing Creams” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, 21 U.S.C. 355h, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as “TKTX Numbing Creams” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesics monograph”).\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “TKTX Numbing Creams” do not conform to the conditions of use specified in the external analgesics monograph for the reasons described below.\u003C\u002Fp>\u003Cp>As formulated, the concentration of active ingredient in your “TKTX Numbing Creams” does not conform to the conditions of use set forth in M017. Specifically, your labeling purports that “Yellow TKTX Numbing Cream 40%,” “White TKTX Numbing Cream 40%,” “Gold TKTX Numbing Cream 40%,” and “Black TKTX Numbing Cream 40%” have a concentration of lidocaine at 5%. This concentration is above the 0.5% to 4% concentration range of lidocaine permitted in M017.\u003C\u002Fp>\u003Cp>Additionally, your labeling purports that “Gold TKTX Numbing Cream 40%” and “Black TKTX Numbing Cream 40%” contain lidocaine in combination with prilocaine. Prilocaine is not permitted as an active ingredient in M017 or any other OTC drug monograph issued in accordance with section 505G.\u003C\u002Fp>\u003Cp>Furthermore, the labeling for your “TKTX Numbing Creams” includes indications that are not consistent with the indications for external analgesic drug products. For example, claims from the product labeling described above related to tattooing, piercing, and laser cosmetic procedures go beyond merely describing the general intended uses for an external analgesic drug product. Indications related to tattooing, piercing, and laser cosmetic procedures are not included in M017 or any other final administrative order in accordance with section 505G. As stated in the introduction to this letter, we have safety concerns related to the use of these products for these indications due to the potential for greater absorption of the active ingredients through irritated or broken skin.\u003C\u002Fp>\u003Cp>Thus, “TKTX Numbing Creams” do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, they are unapproved new drugs. The introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“TKTX Numbing Creams” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with these products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR part 330 prior to enactment of the CARES Act. In the case of OTC external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Refer to FDA public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Refer to the March 26, 2024 news release titled, “FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Ffda-warns-consumers-avoid-certain-topical-pain-relief-products-due-potential-dangerous-health.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions as set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “Yellow TKTX Numbing Cream 40%,” “White TKTX Numbing Cream 40%,” “Gold TKTX Numbing Cream 40%,” and “Black TKTX Numbing Cream 40%” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nTKTX Numbing Cream USA\n\n7831 20th St\n\nWestminster, CA 92683\n\nUnited States\n\ncontact@tktxnumbingcreamusa.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 25, 2025\nRE: 702106\nDear Sir\u002FMadam:\nThis letter concerns your firm’s distribution of the drug products, “Yellow TKTX Numbing Cream 40%,” “White TKTX Numbing Cream 40%,” “Gold TKTX Numbing Cream 40%,” and “Black TKTX Numbing Cream 40%” (hereinafter collectively referred to as “TKTX Numbing Creams”), for use as external analgesics prior to sensitive cosmetic procedures. The United States Food and Drug Administration (FDA) reviewed your product labeling, including your website at the internet address www.tktxnumbingcreamusa.com, where your products are available for purchase in the United States without a prescription.\n“TKTX Numbing Creams” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). “TKTX Numbing Creams” are also misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. 331(a) and (d).\nYour firm markets the above listed drug products as external analgesics to be used before and\u002For during various sensitive cosmetic procedures such as tattooing, laser cosmetic procedures, microblading, and others. These products are marketed without an approved application under section 505 of the FD&C Act for indications that are not included in a final administrative order issued under section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Furthermore, these drug products include lidocaine concentrations that exceed what is permissible for over-the-counter (OTC) external analgesic drug products marketed without an approved application and\u002For include a combination of active ingredients that does not conform to the conditions of marketing in the external analgesics final administrative order issued under section 505G.1\nFDA has safety concerns about your external analgesic drug products, which include certain active ingredients at concentrations that exceed levels currently permitted in such nonprescription drug products, because they are intended to be used before or during certain cosmetic procedures that could lead to increased absorption of the drug product through the skin. FDA is aware that use of these products before and\u002For during a cosmetic procedure may not be supervised by trained health professionals. Without this supervision, large amounts of topical analgesics may be applied to a person’s skin. FDA has specifically warned in multiple public health advisories2 and a recent news release3 about the use of similar lidocaine and other “-caine” type ingredient products when applied over large areas of skin, particularly on irritated or broken skin, for prolonged periods of time, and when the skin is covered after application. These uses increase the amount of active ingredient that passes into the bloodstream and, if used improperly, may cause serious injury.\nUnapproved New Drug and Misbranded Drug Violations\n“TKTX Numbing Creams” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “TKTX Numbing Creams” products’ labeling, including the website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not limited to, the following:\n“Yellow TKTX Numbing Cream 40%”\n“Yellow TKTX Numbing Cream 40% takes the edge off tattoos, piercings, and cosmetic treatments so you can focus on the results you love.” [from the product website]\n“Are you ready to experience a tattoo session that’s more about the art and less about the ouch? At TKTX Numbing Cream USA, we introduce Yellow TKTX Numbing Cream, your go-to solution for a smooth and comfortable tattooing journey.” [from the product website]\n“Yellow TKTX Numbing Cream is crafted with high-quality ingredients, including 5% lidocaine, a proven anesthetic, ensuring a safe and effective numbing experience.” [from the product website]\n“Simply cleanse the area, apply a generous layer, and cover with plastic wrap for 40-60 minutes, and you’re all set for a comfortable tattoo session.” [from the product website]\n“Can I use it for other procedures besides tattoos? While primarily designed for tattoos, Yellow TKTX can also be used for other minor procedures such as piercings and laser hair removal.” [from the product website]\n“White TKTX Numbing Cream 40%”\n“White TKTX Numbing Cream 40% takes the edge off tattoos, piercings, and cosmetic treatments so you can focus on the results you love.” [from the product website]\n“Ready to embrace the artistry of tattoos without the sting? At TKTX Numbing Cream USA, we present White TKTX Numbing Cream, your ultimate solution for a comfortable and enjoyable tattoo session.” [from the product website]\n“White TKTX Numbing Cream is formulated with high-quality ingredients, including 5% lidocaine, a proven anesthetic.” [from the product website]\n“Simply cleanse the area, apply a thick layer, and cover with plastic wrap for 40-60 minutes, and you’re ready for a pain-free tattoo session.” [from the product website]\n“Can I use it for other procedures besides tattoos? While primarily designed for tattoos, White TKTX Numbing Cream can also be used for other minor procedures like piercings and laser hair removal.” [from the product website]\n“Gold TKTX Numbing Cream 40%”\n“Gold TKTX Numbing Cream 40% takes the edge off tattoos, piercings, and cosmetic treatments so you can focus on the results you love.” [from the product website]\n“Are you ready to indulge in a luxurious tattoo experience where pain is a distant memory? At TKTX Numbing Cream USA, we present Gold TKTX Numbing Cream…This premium topical anesthetic is meticulously formulated to provide deep and lasting numbing, ensuring a comfortable and enjoyable tattoo session that feels nothing short of extraordinary.” [from the product website]\n“Gold TKTX Numbing Cream is crafted with the finest ingredients, including a powerful blend of 5% lidocaine and prilocaine, ensuring a safe and effective numbing experience.” [from the product website]\n“Simply cleanse the area, apply a generous layer, cover with plastic wrap for 40-60 minutes, and you’re all set for a comfortable tattoo session.” [from the product website]\n“Can I use it for other procedures besides tattoos? While primarily designed for tattoos, Gold TKTX Numbing Cream can also be used for other minor procedures such as piercings and laser hair removal.” [from the product website]\n“Black TKTX Numbing Cream 40%”\n“Black TKTX Numbing Cream 40% takes the edge off tattoos, piercings, and cosmetic treatments so you can focus on the results you love.” [from the product website]\n“Are you ready to transform your tattoo experience from daunting to delightful? At TKTX Numbing Cream USA, we present Black TKTX Numbing Cream….” [from the product website]\n“Black TKTX Numbing Cream is crafted with high-quality ingredients, including 5% lidocaine and prilocaine, ensuring a safe and effective numbing experience.” [from the product website]\n“Simply cleanse the area, apply a generous layer, and cover with plastic wrap for 40-60 minutes, and you’re ready for a virtually pain-free tattoo session.” [from the product website]\n“Can I use it for other procedures besides tattoos? While primarily intended for tattoos, Black TKTX can also be used for other minor procedures such as piercings and laser hair removal.” [from the product website]\nUnapproved New Drug Violations\nBased on the above labeling evidence “TKTX Numbing Creams” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, 21 U.S.C. 355h, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”— may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as “TKTX Numbing Creams” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, M017: External Analgesic Drug Products for Over-the-Counter Human Use (hereinafter “M017” or the “external analgesics monograph”).4 However, “TKTX Numbing Creams” do not conform to the conditions of use specified in the external analgesics monograph for the reasons described below.\nAs formulated, the concentration of active ingredient in your “TKTX Numbing Creams” does not conform to the conditions of use set forth in M017. Specifically, your labeling purports that “Yellow TKTX Numbing Cream 40%,” “White TKTX Numbing Cream 40%,” “Gold TKTX Numbing Cream 40%,” and “Black TKTX Numbing Cream 40%” have a concentration of lidocaine at 5%. This concentration is above the 0.5% to 4% concentration range of lidocaine permitted in M017.\nAdditionally, your labeling purports that “Gold TKTX Numbing Cream 40%” and “Black TKTX Numbing Cream 40%” contain lidocaine in combination with prilocaine. Prilocaine is not permitted as an active ingredient in M017 or any other OTC drug monograph issued in accordance with section 505G.\nFurthermore, the labeling for your “TKTX Numbing Creams” includes indications that are not consistent with the indications for external analgesic drug products. For example, claims from the product labeling described above related to tattooing, piercing, and laser cosmetic procedures go beyond merely describing the general intended uses for an external analgesic drug product. Indications related to tattooing, piercing, and laser cosmetic procedures are not included in M017 or any other final administrative order in accordance with section 505G. As stated in the introduction to this letter, we have safety concerns related to the use of these products for these indications due to the potential for greater absorption of the active ingredients through irritated or broken skin.\nThus, “TKTX Numbing Creams” do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.5 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, they are unapproved new drugs. The introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\nMisbranded Drug Violations\n“TKTX Numbing Creams” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with these products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________\n1 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs,\" notably, conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR part 330 prior to enactment of the CARES Act. In the case of OTC external analgesic drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use. (See Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\n2 Refer to FDA public health advisories Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures, Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditions, and Improper Use of Skin Numbing Products Can Be Deadly.\n3 Refer to the March 26, 2024 news release titled, “FDA Warns Consumers to Avoid Certain Topical Pain Relief Products Due to Potential for Dangerous Health Effects,” see https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Ffda-warns-consumers-avoid-certain-topical-pain-relief-products-due-potential-dangerous-health.\n4 M017 reflects the conditions as set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf).\n5 FDA is not aware of any adequate and well-controlled clinical studies in the published literature that support a determination that “Yellow TKTX Numbing Cream 40%,” “White TKTX Numbing Cream 40%,” “Gold TKTX Numbing Cream 40%,” and “Black TKTX Numbing Cream 40%” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.","TKTX Numbing Cream USA","tktx-numbing-cream-usa-702106-02252025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftktx-numbing-cream-usa-702106-02252025","2026-10-26T08:10:13.033771+00:00","702106","2026-08-19T17:00:14.517+00:00",{"id":102,"raw":103,"subject":108,"body_html":109,"body_text":110,"firm_name":111,"letter_id":112,"created_at":113,"fei_number":19,"letter_url":114,"updated_at":115,"action_type":22,"case_status":23,"posted_date":116,"marcs_cms_no":117,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":118,"body_fetched_at":119,"delivery_method":120,"recipient_title":19,"reference_number":121,"action_taken_date":122,"medical_device_id":19,"response_letter_date":19},221,[104,105,106,11,107,13,13,13],"\u003Ctime datetime=\"2026-04-21T04:00:00Z\">04\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-14T04:00:00Z\">04\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpro-numb-tattoo-numbing-spray-llc-722589-04142026\">Pro Numb Tattoo Numbing Spray, LLC \u003C\u002Fa>","Nonprescription\u002FOTC\u003Cbr \u002F>\r\n","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-63\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Justin T. Zahnter\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Pro Numb Tattoo Numbing Spray, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3778 Dixie Highway NE, Suite C\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Palm Bay\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32905-2727\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-63\u003C\u002Fp>\u003Cp>April 14, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Zahnter:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pro Numb Tattoo Numbing Spray, LLC, FEI 3027228716, at 3778 Dixie Highway NE, Suite C, Palm Bay, from November 5 to 6, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>Additionally, these drug products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>CGMP Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We reviewed your November 13, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately test batches of your drug products before release and distribution. You stated your firm does not perform finished product testing.\u003C\u002Fp>\u003Cp>In your response, you state you contracted a third-party laboratory to perform full release testing, and you implemented finished product specifications, Certificates of Analysis (COAs), and a standard operating procedure (SOP) for identity, strength, purity, and microbial testing.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient details about the test methods and specifications you implemented for your over-the-counter (OTC) drug products to ensure each batch of your finished products met appropriate standards before release and distribution. Also, you do not commit to performing retrospective testing of your drug product retains (reserve samples) for batches already distributed in the U.S. market.\u003C\u002Fp>\u003Cp>Drug product batches must be tested for identity, strength, quality, and purity before release. Without sufficient release testing, defective drug products that may pose a risk to consumers are unlikely to be detected.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>Procedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC topical analgesic drug products without adequate assurance of the quality of raw materials. For example, you did not test incoming components, such as your active pharmaceutical ingredients, for identity before using them in the manufacture of your drug products. Additionally, you relied on your suppliers’ COAs without establishing the reliability of each of your suppliers’ analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that your raw materials, including but not limited to active pharmaceutical ingredients, conform to the appropriate specifications before their use in the manufacture of your drug products. As a manufacturer, you are responsible for sampling, testing, and examining drug components before their use in production to ensure adequate quality.\u003C\u002Fp>\u003Cp>Your firm also used \u003Cstrong>(b)(4)\u003C\u002Fstrong> from an external source as a component in your finished drug products without conducting adequate testing to ensure it consistently meets the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, United States Pharmacopeia (USP) monograph specifications and appropriate microbial limits.\u003C\u002Fp>\u003Cp>Because \u003Cstrong>(b)(4)\u003C\u002Fstrong> is used as a component in your nonsterile drug products, the lack of data regarding the quality of your incoming \u003Cstrong>(b)(4)\u003C\u002Fstrong> poses a potential risk of introducing objectionable microbial contamination into your products. \u003Cstrong>(b)(4)\u003C\u002Fstrong> purposes must be suitable for its intended use and tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\u003Cp>In your response, you state you created SOPs for raw material receipt, quarantine, sampling, testing, handling, and approval. You also state you implemented raw material testing at a third-party laboratory and implemented testing for your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide raw material specifications, test results, and copies of your SOPs for testing raw materials, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also fail to provide sufficient details demonstrating how you qualified the contract laboratory used for testing raw materials. In addition, your response does not state if you plan to perform retrospective testing for all lots of components already used to manufacture your drug products, and if you plan to establish the reliability of each of your suppliers’ analyses.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality;\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data);\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A procedure for your water testing, including sampling, that also specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to demonstrate the quality attributes of your drug products remain acceptable throughout the labeled expiration period. For example, during the inspection, you indicated to the investigator you recorded microbial results on the stability-study data sheet without performing the testing and without any supporting data. You also did not record assay results on your stability-study data sheets for multiple stability time points.\u003C\u002Fp>\u003Cp>In your response, you explain you have established a compliant stability program, which includes establishing stability SOPs and protocols, implementing accelerated and long-term stability conditions, and submitting initial stability samples to an accredited laboratory. You also state you removed the unsupported \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date while you determine whether the shelf-life is supported by data.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Also, you do not specify the expiration date that you are currently using for your finished products after you removed the \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o all procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003Cli>The current expiry date for your finished drug products.\u003C\u002Fli>\u003Cli>The firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to validate your manufacturing processes for your OTC drug products (for example, Pro Numb Tattoo Numbing Spray 5% Lidocaine and Pro Numb Tattoo Numbing Spray 4% Lidocaine for sensitive skin). When asked to provide validation studies for your manufacturing process, you acknowledged not being familiar with process validation requirements.\u003C\u002Fp>\u003Cp>In addition, the process design and controls for your production did not demonstrate reproducibility or consistency in your manufacturing process. For example, for a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to achieve your target batch size, and then you \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Also, you explained your filling process is to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, without established fill volume controls.\u003C\u002Fp>\u003Cp>Furthermore, you explained you perform viscosity in-process testing of your bulk drug product by looking at it, with a specification of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and without using a viscometer or any other appropriate laboratory instrumentation for your viscosity determination.\u003C\u002Fp>\u003Cp>You did not establish scientifically sound and technically precise process parameters and process controls to ensure quality, homogeneity, and content uniformity, including fill volume of your drug products.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not commit to providing a detailed plan to validate your manufacturing processes.\u003C\u002Fp>\u003Cp>You are responsible for designing and controlling your manufacturing processes to ensure that they reproducibly yield drug products meeting predefined process parameters and quality attributes.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>A timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Establishment of adequate batch production and control records, with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\u003C\u002Fli>\u003Cli>Adequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\u003C\u002Fli>\u003Cli>Establishment of routine calibration and written records of calibration checks according to a written program designed to ensure proper performance of equipment used in the manufacture, processing, packing, and holding of a drug product (21 CFR 211.68(a)).\u003C\u002Fli>\u003Cli>Adequate storage and warehousing of drug products, including but not limited to appropriate monitoring of storage conditions for temperature and humidity (21 CFR 211.142).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state you have established an independent QU; revised and approved all SOPs; remediated your batch manufacturing records; created training files, including complete GMP training of all personnel; implemented an equipment calibration program; and installed calibrated temperature and humidity data loggers with defined storage ranges to monitor your storage areas.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide sufficient information and supporting documentation to verify the adequacy and effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>ICH Q10 Pharmaceutical Quality System, as well as Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, respectively.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A complete, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>Your QU authority and responsibilities procedure, SOP-QA-001.\u003C\u002Fli>\u003Cli>Your organizational chart and current number of CGMP employees.\u003C\u002Fli>\u003Cli>Your procedure for your environmental controls and alarm limits for your storage areas.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products’ labeling, including your website, https:\u002F\u002Ftattoonumbingsprays.com\u002F, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cu>PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN\u003C\u002Fu>”\u003Cbr>“Topical Anesthetic to take away pain” [from your product labels]\u003C\u002Fp>\u003Cp>“Takes away Pain, Swelling, and Redness during tattoo procedures” [from your product labels]\u003C\u002Fp>\u003Cp>“Temporarily takes away pain, itching, and swelling associated with anorectal disorders or pain-sensitive procedures” [from your product labels]\u003C\u002Fp>\u003Cp>“Instantly removes pain…” [from your product website]\u003C\u002Fp>\u003Cp>“Tattoo Pain Relief” [from your product website]\u003C\u002Fp>\u003Cp>\u003Cu>“PRO NUMB TATTOO NUMBING SPRAY”\u003C\u002Fu>\u003Cbr>“5% lidocaine temporarily blocks pain signals in the brain” [from your product website]\u003C\u002Fp>\u003Cp>\u003Cu>“PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN”\u003C\u002Fu>\u003Cbr>“4% lidocaine temporarily blocks pain signals in the brain” [from your product website]\u003C\u002Fp>\u003Cp>\u003Cu>“TKTX Deep Numbs”\u003C\u002Fu>\u003Cbr>“Usable Range Micro Needle Pain Tattooing Body Piercing, Laser Tattoo Removal, Laser Hair Removal, Waxing, Permanent Cosmetics” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are intended for use as external analgesic drug products, among other intended uses.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” do not conform to the conditions specified in M017 for the reasons described below.\u003C\u002Fp>\u003Cp>The labeled concentrations and\u002For combinations of active ingredients identified in the product labeling for “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” do not conform to the conditions of use set forth in M017. Specifically, lidocaine, an active ingredient labeled to be in all three products, is listed as lidocaine 5% in “TKTX Deep Numbs” and lidocaine hydrochloride 5% in “PRO NUMB TATTOO NUMBING SPRAY.” This concentration is above the 0.5% to 4% concentration range of lidocaine and lidocaine hydrochloride permitted under M017.10(a).\u003C\u002Fp>\u003Cp>As formulated, both “PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN” contain a combination of the active ingredients lidocaine and epinephrine, and “TKTX Deep Numbs” contains a combination of the active ingredients lidocaine, epinephrine, and prilocaine. None of these combinations of active ingredients in a single external analgesic drug product are permitted under M017.20. Furthermore, epinephrine, epinephrine HCl, and prilocaine are not permitted ingredients under M017, and prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\u003C\u002Fp>\u003Cp>Additionally, the labeling for “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” includes indications that are not permitted for external analgesic drug products under M017.50(b). Indications related to tattooing, piercing, and\u002For minor cosmetic procedures are not permitted under M017 or in any other final administrative order in accordance with section 505G.\u003C\u002Fp>\u003Cp>Thus, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drugs into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of any applications approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355. The introduction or delivery for introduction of misbranded drugs into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On January 28, 2026, FDA held a teleconference with you recommending you consider removing any batches of Pro Numb Tattoo Numbing Spray and Pro Numb Tattoo Numbing Spray for Sensitive Skin currently in distribution from the U.S. market.\u003C\u002Fp>\u003Cp>You communicated your commitment to voluntary recall all batches of your Pro Numb Tattoo Numbing Spray drug products within expiry.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3027228716 and ATTN: Sai Dharmaraj.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that “PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN” also appear to be indicated to relieve pain associated with anorectal disorders. OTC anorectal drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use (“M015”). (See Order ID OTC000009, available at FDA’s website OTC Monographs@FDA). These products also do not conform to the conditions set forth in this monograph.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfm.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-63\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Justin T. Zahnter\n\nRecipient Title\n\nOwner\n\nPro Numb Tattoo Numbing Spray, LLC\n\n3778 Dixie Highway NE, Suite C\n\nPalm Bay, FL 32905-2727\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-63\nApril 14, 2026\nDear Mr. Zahnter:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Pro Numb Tattoo Numbing Spray, LLC, FEI 3027228716, at 3778 Dixie Highway NE, Suite C, Palm Bay, from November 5 to 6, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nAdditionally, these drug products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nCGMP Violations\nWe reviewed your November 13, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYour firm failed to adequately test batches of your drug products before release and distribution. You stated your firm does not perform finished product testing.\nIn your response, you state you contracted a third-party laboratory to perform full release testing, and you implemented finished product specifications, Certificates of Analysis (COAs), and a standard operating procedure (SOP) for identity, strength, purity, and microbial testing.\nYour response is inadequate. You do not provide sufficient details about the test methods and specifications you implemented for your over-the-counter (OTC) drug products to ensure each batch of your finished products met appropriate standards before release and distribution. Also, you do not commit to performing retrospective testing of your drug product retains (reserve samples) for batches already distributed in the U.S. market.\nDrug product batches must be tested for identity, strength, quality, and purity before release. Without sufficient release testing, defective drug products that may pose a risk to consumers are unlikely to be detected.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nProcedure(s) describing how your firm maintains drug product retains (reserve samples) for each batch manufactured at your facility.\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product release testing.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC topical analgesic drug products without adequate assurance of the quality of raw materials. For example, you did not test incoming components, such as your active pharmaceutical ingredients, for identity before using them in the manufacture of your drug products. Additionally, you relied on your suppliers’ COAs without establishing the reliability of each of your suppliers’ analyses at appropriate intervals.\nWithout adequate testing, you do not have scientific evidence that your raw materials, including but not limited to active pharmaceutical ingredients, conform to the appropriate specifications before their use in the manufacture of your drug products. As a manufacturer, you are responsible for sampling, testing, and examining drug components before their use in production to ensure adequate quality.\nYour firm also used (b)(4) from an external source as a component in your finished drug products without conducting adequate testing to ensure it consistently meets the (b)(4), United States Pharmacopeia (USP) monograph specifications and appropriate microbial limits.\nBecause (b)(4) is used as a component in your nonsterile drug products, the lack of data regarding the quality of your incoming (b)(4) poses a potential risk of introducing objectionable microbial contamination into your products. (b)(4) purposes must be suitable for its intended use and tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\nIn your response, you state you created SOPs for raw material receipt, quarantine, sampling, testing, handling, and approval. You also state you implemented raw material testing at a third-party laboratory and implemented testing for your (b)(4), including testing for (b)(4).\nYour response is inadequate. You do not provide raw material specifications, test results, and copies of your SOPs for testing raw materials, including (b)(4). You also fail to provide sufficient details demonstrating how you qualified the contract laboratory used for testing raw materials. In addition, your response does not state if you plan to perform retrospective testing for all lots of components already used to manufacture your drug products, and if you plan to establish the reliability of each of your suppliers’ analyses.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified;\no an assessment of all materials to determine whether they are consistently of acceptable quality;\no a review to ensure assigned expiration or retest dates are appropriate (supported by data);\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systems corrective action and preventive action (CAPA) to remediate the supplier qualification program and prevent use of unsuitable components, containers and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your suppliers’ COAs instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA procedure for your water testing, including sampling, that also specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nThe firm name, address, and supplier qualification report, for your third-party laboratory or laboratories conducting your raw material testing.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nYou failed to demonstrate the quality attributes of your drug products remain acceptable throughout the labeled expiration period. For example, during the inspection, you indicated to the investigator you recorded microbial results on the stability-study data sheet without performing the testing and without any supporting data. You also did not record assay results on your stability-study data sheets for multiple stability time points.\nIn your response, you explain you have established a compliant stability program, which includes establishing stability SOPs and protocols, implementing accelerated and long-term stability conditions, and submitting initial stability samples to an accredited laboratory. You also state you removed the unsupported (b)(4) expiration date while you determine whether the shelf-life is supported by data.\nYour response is inadequate. You do not describe in detail your stability plan with defined stability conditions, time points, and testing of the appropriate critical quality attributes for drug stability, including but not limited to microbiological and impurity testing. Also, you do not specify the expiration date that you are currently using for your finished products after you removed the (b)(4) expiration date.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive, independent investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no detailed definition of the specific attributes to be tested at each station (timepoint)\no all procedures that describe these and other elements of your remediated stability program.\nThe current expiry date for your finished drug products.\nThe firm name, address, and supplier qualification report for the third-party laboratory or laboratories conducting your drug product stability testing.\n4. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm failed to validate your manufacturing processes for your OTC drug products (for example, Pro Numb Tattoo Numbing Spray 5% Lidocaine and Pro Numb Tattoo Numbing Spray 4% Lidocaine for sensitive skin). When asked to provide validation studies for your manufacturing process, you acknowledged not being familiar with process validation requirements.\nIn addition, the process design and controls for your production did not demonstrate reproducibility or consistency in your manufacturing process. For example, for a (b)(4) to achieve your target batch size, and then you (b)(4). Also, you explained your filling process is to (b)(4), without established fill volume controls.\nFurthermore, you explained you perform viscosity in-process testing of your bulk drug product by looking at it, with a specification of “(b)(4),” and without using a viscometer or any other appropriate laboratory instrumentation for your viscosity determination.\nYou did not establish scientifically sound and technically precise process parameters and process controls to ensure quality, homogeneity, and content uniformity, including fill volume of your drug products.\nYour response is inadequate. You do not commit to providing a detailed plan to validate your manufacturing processes.\nYou are responsible for designing and controlling your manufacturing processes to ensure that they reproducibly yield drug products meeting predefined process parameters and quality attributes.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA’s guidance document, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nAn assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nA timeline for performing process performance qualification (PPQ) for each of your marketed drug products. Also provide a risk assessment and any follow up actions to be taken for the distributed drug products produced without performing any process validation studies.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control throughout the product lifecycle. Also, include your program for qualification of your equipment and facility.\nA comprehensive, independent assessment of your in-process monitoring and sampling operations, focusing on each upstream process step that can introduce variability. Provide your remediation plan to improve: (1) upstream process controls; (2) in-process detection of variation; and (3) sampling plans.\n5. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\nEstablishment of adequate batch production and control records, with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).\nAdequate training for employees engaged in the manufacture, processing, packing, or holding of drug products (21 CFR 211.25(a)).\nEstablishment of routine calibration and written records of calibration checks according to a written program designed to ensure proper performance of equipment used in the manufacture, processing, packing, and holding of a drug product (21 CFR 211.68(a)).\nAdequate storage and warehousing of drug products, including but not limited to appropriate monitoring of storage conditions for temperature and humidity (21 CFR 211.142).\nIn your response, you state you have established an independent QU; revised and approved all SOPs; remediated your batch manufacturing records; created training files, including complete GMP training of all personnel; implemented an equipment calibration program; and installed calibrated temperature and humidity data loggers with defined storage ranges to monitor your storage areas.\nYour response is inadequate. You do not provide sufficient information and supporting documentation to verify the adequacy and effectiveness of your corrective actions.\nYour firm’s quality systems are inadequate. See FDA’s guidance document ICH Q10 Pharmaceutical Quality System, as well as Quality Systems Approach to Pharmaceutical CGMP Regulations, for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload and https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload, respectively.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA complete, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nYour QU authority and responsibilities procedure, SOP-QA-001.\nYour organizational chart and current number of CGMP employees.\nYour procedure for your environmental controls and alarm limits for your storage areas.\nUnapproved New Drug and Misbranded Drug Violations\n“PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products’ labeling, including your website, https:\u002F\u002Ftattoonumbingsprays.com\u002F, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products as drugs include, but may not be limited to, the following:\n“PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN”\n“Topical Anesthetic to take away pain” [from your product labels]\n“Takes away Pain, Swelling, and Redness during tattoo procedures” [from your product labels]\n“Temporarily takes away pain, itching, and swelling associated with anorectal disorders or pain-sensitive procedures” [from your product labels]\n“Instantly removes pain…” [from your product website]\n“Tattoo Pain Relief” [from your product website]\n“PRO NUMB TATTOO NUMBING SPRAY”\n“5% lidocaine temporarily blocks pain signals in the brain” [from your product website]\n“PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN”\n“4% lidocaine temporarily blocks pain signals in the brain” [from your product website]\n“TKTX Deep Numbs”\n“Usable Range Micro Needle Pain Tattooing Body Piercing, Laser Tattoo Removal, Laser Hair Removal, Waxing, Permanent Cosmetics” [from the product label]\nUnapproved New Drug Violations\nBased on the above labeling evidence, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are intended for use as external analgesic drug products, among other intended uses.1 As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for the drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, Over-the-Counter Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (“M017”).2 However, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” do not conform to the conditions specified in M017 for the reasons described below.\nThe labeled concentrations and\u002For combinations of active ingredients identified in the product labeling for “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” do not conform to the conditions of use set forth in M017. Specifically, lidocaine, an active ingredient labeled to be in all three products, is listed as lidocaine 5% in “TKTX Deep Numbs” and lidocaine hydrochloride 5% in “PRO NUMB TATTOO NUMBING SPRAY.” This concentration is above the 0.5% to 4% concentration range of lidocaine and lidocaine hydrochloride permitted under M017.10(a).\nAs formulated, both “PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN” contain a combination of the active ingredients lidocaine and epinephrine, and “TKTX Deep Numbs” contains a combination of the active ingredients lidocaine, epinephrine, and prilocaine. None of these combinations of active ingredients in a single external analgesic drug product are permitted under M017.20. Furthermore, epinephrine, epinephrine HCl, and prilocaine are not permitted ingredients under M017, and prilocaine is not a permitted active ingredient in any final administrative order issued in accordance with section 505G.\nAdditionally, the labeling for “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” includes indications that are not permitted for external analgesic drug products under M017.50(b). Indications related to tattooing, piercing, and\u002For minor cosmetic procedures are not permitted under M017 or in any other final administrative order in accordance with section 505G.\nThus, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.3 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction of these unapproved new drugs into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of any applications approved under section 505 of the FD&C Act, 21 U.S.C. 355. The introduction or delivery for introduction of misbranded drugs into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nDrug Recall\nOn January 28, 2026, FDA held a teleconference with you recommending you consider removing any batches of Pro Numb Tattoo Numbing Spray and Pro Numb Tattoo Numbing Spray for Sensitive Skin currently in distribution from the U.S. market.\nYou communicated your commitment to voluntary recall all batches of your Pro Numb Tattoo Numbing Spray drug products within expiry.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit4 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3027228716 and ATTN: Sai Dharmaraj.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________\n1 We note that “PRO NUMB TATTOO NUMBING SPRAY” and “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN” also appear to be indicated to relieve pain associated with anorectal disorders. OTC anorectal drug products are deemed to be GRASE and not new drugs if, among other things, they conform to the conditions of use set forth in the final administrative order, Over-the-Counter Monograph M015: Anorectal Drug Products for Over-the-Counter Human Use (“M015”). (See Order ID OTC000009, available at FDA’s website OTC Monographs@FDA). These products also do not conform to the conditions set forth in this monograph.\n2 M017 reflects the conditions set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002Findex.cfm.\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “PRO NUMB TATTOO NUMBING SPRAY,” “PRO NUMB TATTOO NUMBING SPRAY FOR SENSITIVE SKIN,” and “TKTX Deep Numbs” products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\n4 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Pro Numb Tattoo Numbing Spray, LLC","pro-numb-tattoo-numbing-spray-llc-722589-04142026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpro-numb-tattoo-numbing-spray-llc-722589-04142026","2026-10-26T08:09:44.392139+00:00","2026-04-21","722589","Mr. Justin T. Zahnter","2026-08-19T04:46:38.526+00:00","VIA EMAIL WITH READ RECEIPT","320-26-63","2026-04-14",{"id":124,"raw":125,"subject":130,"body_html":131,"body_text":132,"firm_name":133,"letter_id":134,"created_at":135,"fei_number":19,"letter_url":136,"updated_at":137,"action_type":22,"case_status":23,"posted_date":138,"marcs_cms_no":139,"product_type":140,"closeout_date":19,"issuing_office":129,"recipient_name":141,"body_fetched_at":142,"delivery_method":143,"recipient_title":19,"reference_number":19,"action_taken_date":144,"medical_device_id":19,"response_letter_date":19},2681,[126,127,128,129,130,13,13,13],"\u003Ctime datetime=\"2022-05-09T16:00:00Z\">05\u002F09\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-04T04:00:00Z\">05\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutritional-supplements-llc-622055-05042022\">Advanced Nutritional Supplements LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Dietary Supplement\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brandon March\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Advanced Nutritional Supplements LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3872 Union Deposit Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Harrisburg\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>17109\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. March:\u003C\u002Fp>\n\n\u003Cp>This letter concerns your products New God of Rage, God of War, New God of Fire, Legion: Extreme Fat Burner, Laxovar: Natural Recomposition, and Uprising: Natural Testosterone Support which are labeled as dietary supplements. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) because the products are adulterated dietary supplements. You can find the FD&amp;C Act through links on FDA’s website at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Flaws-enforced-fda\u002Ffederal-food-drug-andcosmetic-act-fdc-act, and the FDA regulations at https:\u002F\u002Fwww.ecfr.gov\u002Fcurrent\u002Ftitle-21.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements: Unsafe Food Additives\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>The labels of the following products declare dietary ingredients: New God of Rage declares higenamine HCl &amp; hordenine HCl, God of War declares hordenine HCl, New God of Fire declares hordenine HCl, Legion: Extreme Fat Burner declares higenamine HCl, Laxovar: Natural Recomposition declares 5ahydroxy-laxogenin, an abbreviated name for 5-alpha-hydroxy-laxogenin\u003Ca id=\"footnoteref1_rujmm7u\" href=\"#footnote1_rujmm7u\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>, and Uprising: Natural Testosterone Support declares 5-alpha-hydroxy-laxogenin. However, higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin are not dietary ingredients. Under section 201(ff)(1) of the FD&amp;C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin do not qualify as dietary ingredients under section 201(ff)(1) of the FD&amp;C Act because they are not a vitamin, a mineral, an amino acid, an herb or other botanical, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or a combination of any dietary ingredient from the preceding categories.\u003C\u002Fp>\n\n\u003Cp>If a substance is not generally recognized as safe (GRAS) by qualified experts for its intended use in food and does not qualify for any of the other exemptions from the food additive definition, it is a food additive. Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)]. Adulterated foods cannot be legally imported or marketed in the United States.\u003C\u002Fp>\n\n\u003Cp>Section 201(s) of the FD&amp;C Act [21 U.S.C § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements, such as the higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin used in your products, are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. In other words, a non-dietary ingredient added to a dietary supplement must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\u003C\u002Fp>\n\n\u003Cp>Higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin are not generally recognized as safe under its conditions of use in your dietary supplement products. Because higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin do not qualify as dietary ingredients and are not GRAS or otherwise exempt from the food additive definition, your New God of Rage, God of War, New God of Fire, Legion: Extreme Fat Burner, Laxovar: Natural Recomposition, and Uprising: Natural Testosterone Support products are adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act because they contain unsafe food additives. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Aaron Dotson, Compliance Officer, via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\u003Col>\n                  \u003Cli id=\"footnote1_rujmm7u\">\u003Ca href=\"#footnoteref1_rujmm7u\">1\u003C\u002Fa>Chemists commonly use “a” as an abbreviation for “alpha.”\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nBrandon March\n\nAdvanced Nutritional Supplements LLC\n\n3872 Union Deposit Rd\n\nHarrisburg, PA 17109\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nDear Mr. March:\n\nThis letter concerns your products New God of Rage, God of War, New God of Fire, Legion: Extreme Fat Burner, Laxovar: Natural Recomposition, and Uprising: Natural Testosterone Support which are labeled as dietary supplements. As explained further below, introducing or delivering these products for introduction into interstate commerce violates the Federal Food, Drug, and Cosmetic Act (the FD&C Act) because the products are adulterated dietary supplements. You can find the FD&C Act through links on FDA’s website at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Flaws-enforced-fda\u002Ffederal-food-drug-andcosmetic-act-fdc-act, and the FDA regulations at https:\u002F\u002Fwww.ecfr.gov\u002Fcurrent\u002Ftitle-21.\n\nAdulterated Dietary Supplements: Unsafe Food Additives\n\nThe labels of the following products declare dietary ingredients: New God of Rage declares higenamine HCl & hordenine HCl, God of War declares hordenine HCl, New God of Fire declares hordenine HCl, Legion: Extreme Fat Burner declares higenamine HCl, Laxovar: Natural Recomposition declares 5ahydroxy-laxogenin, an abbreviated name for 5-alpha-hydroxy-laxogenin1, and Uprising: Natural Testosterone Support declares 5-alpha-hydroxy-laxogenin. However, higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin are not dietary ingredients. Under section 201(ff)(1) of the FD&C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. Higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin do not qualify as dietary ingredients under section 201(ff)(1) of the FD&C Act because they are not a vitamin, a mineral, an amino acid, an herb or other botanical, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract, or a combination of any dietary ingredient from the preceding categories.\n\nIf a substance is not generally recognized as safe (GRAS) by qualified experts for its intended use in food and does not qualify for any of the other exemptions from the food additive definition, it is a food additive. Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)]. Adulterated foods cannot be legally imported or marketed in the United States.\n\nSection 201(s) of the FD&C Act [21 U.S.C § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements, such as the higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin used in your products, are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. In other words, a non-dietary ingredient added to a dietary supplement must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\n\nHigenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin are not generally recognized as safe under its conditions of use in your dietary supplement products. Because higenamine HCl, hordenine HCl, and 5-alpha-hydroxy-laxogenin do not qualify as dietary ingredients and are not GRAS or otherwise exempt from the food additive definition, your New God of Rage, God of War, New God of Fire, Legion: Extreme Fat Burner, Laxovar: Natural Recomposition, and Uprising: Natural Testosterone Support products are adulterated under section 402(a)(2)(C)(i) of the FD&C Act because they contain unsafe food additives. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Aaron Dotson, Compliance Officer, via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n1Chemists commonly use “a” as an abbreviation for “alpha.”","Advanced Nutritional Supplements LLC","advanced-nutritional-supplements-llc-622055-05042022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutritional-supplements-llc-622055-05042022","2026-10-26T08:07:50.550656+00:00","2022-05-09","622055","Dietary Supplements","Brandon March","2026-08-20T01:55:24.118+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-05-04",{"id":146,"raw":147,"subject":152,"body_html":154,"body_text":155,"firm_name":156,"letter_id":157,"created_at":158,"fei_number":19,"letter_url":159,"updated_at":160,"action_type":22,"case_status":161,"posted_date":162,"marcs_cms_no":163,"product_type":26,"closeout_date":164,"issuing_office":151,"recipient_name":165,"body_fetched_at":166,"delivery_method":167,"recipient_title":19,"reference_number":19,"action_taken_date":168,"medical_device_id":19,"response_letter_date":19},3024,[148,149,150,151,152,13,153,13],"\u003Ctime datetime=\"2021-11-16T14:20:00Z\">11\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-10T05:00:00Z\">11\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021\">Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\u003C\u002Fa>","Division of Pharmaceutical Quality Operations Division III","Compounding Pharmacy\u002FAdulterated Drug Products","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-02242026\">\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Leonard D. Guyer, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Medical Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>836 E. 86th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Indianapolis\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46240-1806\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations Division III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL # 615908\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 10, 2021\u003Cbr>\n\u003Cbr>\nDear Dr. Guyer:\u003C\u002Fp>\n\n\u003Cp>From October 13, 2020, to October 29, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Advanced Nutriceuticals LLC dba The Guyer Institute of Molecular Medicine located at 836 E. 86th Street, Indianapolis, Indiana 46240. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on October 29, 2020. FDA acknowledges receipt of your facility’s response, dated November 18, 2020. Additionally, FDA acknowledges that your firm voluntarily ceased sterile production while corrective actions are implemented and, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a state licensed pharmacy or a federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503A\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators collected evidence indicating:\u003C\u002Fp>\n\n\u003Cp>1. Your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced, such as your “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” products, including Energy Boost.\u003C\u002Fp>\n\n\u003Cp>2. Your firm compounded drug products using \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Drug products compounded using \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not eligible for the exemptions provided by section 503A(a), because \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not the subject of an applicable USP or NF monograph, are not components of FDA-approved human drugs, and do not appear on the 503A bulks list.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Therefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. Your operator was observed conducting aseptic operations outside of a certified ISO 5 area. The filling of sterile drug products into syringes, which were not for immediate administration to patients, but for shipment to patients across the country, was conducted in the unclassified dispensary area by personnel in street clothes with no gloves donned.\u003C\u002Fp>\n\n\u003Cp>2. Your “IV Hood” used to produce drug products purporting to be sterile is located in an unclassified room. In addition, this hood has not been certified in over two years.\u003C\u002Fp>\n\n\u003Cp>3. Your personnel performing sterile operations have never conducted media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>4. Your operator engaged in aseptic processing while wearing non-sterile gloves, street clothes, and with exposed skin within the ISO 5 aseptic processing area.\u003C\u002Fp>\n\n\u003Cp>5. Your personnel engaged in poor aseptic technique on multiple occasions during the processing of sterile drug products. For example:\u003Cbr>\n&nbsp; a. An operator placed their gloved hands outside the ISO 5 work area repeatedly to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\u003Cbr>\n&nbsp; b. An operator failed to sanitize or change gloves after contact with non-sterile materials (e.g., face mask, trash can) during sterile processing.\u003Cbr>\n&nbsp; c. An operator blocked first air by placing gloved hands directly in line with the sterile filter and open sterile containers.\u003C\u002Fp>\n\n\u003Cp>6. An operator was observed manually stoppering sterile drug vials and touching product contact surfaces during the process.\u003C\u002Fp>\n\n\u003Cp>7. Your firm exposed a stock solution intended to be sterile to worse than ISO 5 air after the stopper had been punctured multiple times. Specifically, the stock solution was stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period.\u003C\u002Fp>\n\n\u003Cp>8. Your firm stores unused product vials in non-sterile plastic bags, which are allowed to be reused in sterile production. The vials stored in these bags are not \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Moreover, your firm’s temperature and time conditions used for \u003Cstrong>(b)(4)\u003C\u002Fstrong> of product vials are not known to be \u003Cstrong>(b)(4)\u003C\u002Fstrong> microorganisms.\u003C\u002Fp>\n\n\u003Cp>9. Your firm has not conducted environmental monitoring since 2018.\u003C\u002Fp>\n\n\u003Cp>10. Your aseptic processing and surrounding areas had difficult to clean and visibly dirty equipment or surfaces. For example:\u003Cbr>\n&nbsp; a. HEPA filters were discolored and\u002For damaged in the ISO 5 cleanroom hood.\u003Cbr>\n&nbsp; b. Your ISO 5 cleanroom workbench was constructed of laminated wood.\u003Cbr>\n&nbsp; c. A heating vent located below the ISO 5 cleanroom hood was visibly dirty and had no filtering device.\u003C\u002Fp>\n\n\u003Cp>11. Your firm handled hazardous drugs without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>Furthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations included, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\n\n\u003Cp>5. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)).\u003C\u002Fp>\n\n\u003Cp>6. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fp>\n\n\u003Cp>7. Your firm failed to prepare batch production and control records for each batch of drug product that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\u003C\u002Fp>\n\n\u003Cp>8. Your firm failed to retest or reexamine components, as appropriate, for identity, strength, quality, and purity and your quality control unit failed to approve or reject components (21 CFR 211.87).\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for the ineligible drug products that you compounded.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483. We acknowledge that your firm voluntarily ceased sterile production while corrective actions are implemented and, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, some of your corrective actions appear adequate. Furthermore, we acknowledge your intention to install new modular cleanrooms in a separate building on your property to be used for sterile operations in the future. However, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation. For example:\u003C\u002Fp>\n\n\u003Cp>1. Your response to multiple observations includes the creation or revision of procedures and\u002For personnel training. None of the pertinent documentation was provided.\u003C\u002Fp>\n\n\u003Cp>2. You committed to the cessation of pre-filling syringes for shipment to patients. Your response states that staff have been counseled and refresher training on proper aseptic technique would be completed, but no documentation related to this was provided.\u003C\u002Fp>\n\n\u003Cp>3. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but no further details about the kits were provided. It cannot be determined from the available information if the kits \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>4. Your response states you intend \u003Cstrong>(b)(4)\u003C\u002Fstrong> building which will include \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No additional information or supporting documentation was provided regarding this renovation; no response updates have been received.\u003C\u002Fp>\n\n\u003Cp>5. Your response states your firm has implemented several corrections such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. No supporting documentation was provided for those corrective actions. No additional information was provided related to the ISO 5 hood with the laminated work surface, which you stated you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>6. Your response states that you plan to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but intend to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, no information was provided about the type of equipment and proposed timeline for this corrective action.\u003C\u002Fp>\n\n\u003Cp>7. Your response states that you would \u003Cstrong>(b)(4)\u003C\u002Fstrong> which would be more conducive to maneuvering in the cleanroom. It is unclear whether this is referring to \u003Cstrong>(b)(4)\u003C\u002Fstrong> to go inside the hood or beside the hood. If inside, dynamic smoke studies have not been provided to evaluate the effect of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on laminar airflow.\u003C\u002Fp>\n\n\u003Cp>If outside the hood, employees may continue to have issues reaching in and out of the hood to retrieve needed supplies during sterile operations.\u003C\u002Fp>\n\n\u003Cp>8. Your response did not provide sufficient detail for an evaluation of your corrections related to the handling of hazardous drugs to prevent cross contamination.\u003C\u002Fp>\n\n\u003Cp>9. Your response refers to staff members responsible for administering IVs being allowed to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear which staff members this refers to, where this operation is to occur, and whether those employees will also be conducting \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You did not address certain observations related to insanitary conditions, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> building on the property. The response does not address how or if the current ISO 7\u002F8 suite of rooms will be used in the future.\u003C\u002Fp>\n\n\u003Cp>2. Your response states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> units to be installed but does not address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> monitoring in your current classified areas.\u003C\u002Fp>\n\n\u003Cp>3. Your response did not address the lack of \u003Cstrong>(b)(4)\u003C\u002Fstrong> by your operators during aseptic production.\u003C\u002Fp>\n\n\u003Cp>4. Your response failed to address your lack of routine environmental monitoring.\u003C\u002Fp>\n\n\u003Cp>5. Your response did not address what actions, if any, were taken to ensure the IV hood located in the unclassified room is no longer used.\u003C\u002Fp>\n\n\u003Cp>6. Your response did not address the cleaning and mitigation of the visible drug residues on your current shared equipment that was observed during the inspection.\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. Your response states that opened vials will \u003Cstrong>(b)(4)\u003C\u002Fstrong> from opening or the date of expiry and the vials will only be \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response did not provide justification for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear if the stoppers for your stock vials, which are prepared in house, are intended for&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response states that employees have been instructed to visually inspect stock solution vials. Visual inspection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials is not a suitable indicator that the product remains sterile. Your response does not demonstrate how you will prevent contamination when \u003Cstrong>(b)(4)\u003C\u002Fstrong>, with or without use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are stored outside of an ISO 5 environment.\u003Cbr>\n\u003Cbr>\n2. Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product vials; however, your response states you are \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which would not be suitable for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It is unclear whether your firm has purchased \u003Cstrong>(b)(4)\u003C\u002Fstrong> for sterilization of the product vials. Your response does not address the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of product vials. You provided no information demonstrating that the current \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle is adequate. Your response does not address the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> during sterilization or \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The use of vials that have not been adequately \u003Cstrong>(b)(4)\u003C\u002Fstrong>, even if adequately sterilized \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is not an acceptable practice.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>In addition, it appears you may have been compounding using the bulk drug substance piracetam. Drug products compounded using bulk piracetam are not eligible for the exemptions provided by section 503A(a), because piracetam is not the subject of an applicable USP or NF monograph, not a component of an FDA-approved human drug and does not appear on the 503A bulks list.\u003C\u002Fp>\n\n\u003Cp>Furthermore, it appears that your facility may have produced biological products. Please be advised that federal law does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved biologics license application (BLA). Specifically, section 351(a)(1) of the Public Health Service Act (PHS Act) prohibits the introduction into interstate commerce of any biological product unless “a biologics license . . . is in effect for the biological product” (i.e., an approved BLA). Additionally, biological products subject to licensure under section 351 of the PHS Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. We also note that, as required by the Biologics Price Competition and Innovation Act of 2009, on March 23, 2020, an approved application for a biological product under section 505 of the FDCA was deemed to be a license for the biological product (i.e., an approved BLA) under the PHS Act. This transition affects compounding under sections 503A and 503B of the FDCA because, beginning on March 23, 2020, these biological products that previously could have been submitted in a marketing application under the FD&amp;C Act are subject to licensure under section 351 of the PHS Act and thus are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. \u003Cem>See\u003C\u002Fem> \u003Cem>Notice to Compounders: Changes that affect compounding as of March 23, 2020\u003C\u002Fem>\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 for additional information. Although these biological products are not eligible for the exemptions in sections 503A and 503B, FDA issued guidance explaining the conditions under which we do not intend to take action when certain biological products are mixed, diluted, or repackaged in a manner not described in their approved labeling. See Guidance for Industry: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>Lastly, during the inspection, investigators noted that your firm may be exporting products to other countries. Please be advised that if a product meets the FDCA’s requirements for sale and distribution in the United States, the FDCA has no additional restrictions on its exportation (i.e., sections 801 and 802 of the FDCA [21 U.S.C. § 381 and 382] do not apply to such exports). However, if the product does not meet FDCA’s domestic marketing requirements and is intended for export then you are required to be in compliance with applicable sections of the FDCA Chapter VIII – Imports and Exports. Furthermore, other federal statutes or regulations administered by other federal agencies (such as the Department of Commerce) may apply. For further information please see FDA’s Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996\u003C\u002Fa>).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>If you decide to resume sterile operations, you should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to address any violations, or you may inform us that you do not intend to resume production of sterile drugs. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (615908). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Tina M. Pawlowski, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nicholas F. Lyons\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On June 9, 2016, FDA issued a final guidance titled, \u003Cem>Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fem>. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Cerebrolysin, thymosin alpha, thymosin beta, BPC-157, LL-37, pentosan, Selank, and Semax were not nominated for inclusion on the 503A bulks list. For additional information, see the guidance at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\">http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLeonard D. Guyer, MD\n\nRecipient Title\n\nFounder and Medical Director\n\nAdvanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine\n\n836 E. 86th Street\n\nIndianapolis, IN 46240-1806\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations Division III\n\nUnited States\n\nWARNING LETTER\n\nWL # 615908\n\nNovember 10, 2021\n\nDear Dr. Guyer:\n\nFrom October 13, 2020, to October 29, 2020, U.S. Food and Drug Administration (FDA) investigators inspected your facility, Advanced Nutriceuticals LLC dba The Guyer Institute of Molecular Medicine located at 836 E. 86th Street, Indianapolis, Indiana 46240. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353a] for exemption from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing sterile drug products, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on October 29, 2020. FDA acknowledges receipt of your facility’s response, dated November 18, 2020. Additionally, FDA acknowledges that your firm voluntarily ceased sterile production while corrective actions are implemented and, on (b)(4), initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the FDCA.\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a state licensed pharmacy or a federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1 Receipt of valid prescriptions for individually-identified patients is one of the conditions for the exemptions under section 503A.\n\nIn addition, for a compounded drug product to qualify for the exemptions under section 503A, bulk drug substances used to compound it must: (I) comply with the standards of an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, if a monograph exists, and the USP chapter on pharmacy compounding; (II) if such a monograph does not exist, be components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, appear on a list developed by the Secretary through regulation (“503A bulks list”) (section 503A(b)(1)(A)(i) of the FDCA).\n\nB. Failure to Meet the Conditions of Section 503A\n\nDuring the inspection, the FDA investigators collected evidence indicating that drug products produced by your firm failed to meet the conditions of section 503A. For example, the investigators collected evidence indicating:\n\n1. Your firm did not receive valid prescriptions for individually-identified patients for a portion of the drug products you produced, such as your “(b)(4)” products, including Energy Boost.\n\n2. Your firm compounded drug products using (b)(4). Drug products compounded using (b)(4), and (b)(4) are not eligible for the exemptions provided by section 503A(a), because (b)(4), and (b)(4) are not the subject of an applicable USP or NF monograph, are not components of FDA-approved human drugs, and do not appear on the 503A bulks list.2\n\nTherefore, you compounded drug products that do not meet the conditions of section 503A and are not eligible for the exemptions in that section, including the FDA approval requirement of section 505 of the FDCA, the requirement under section 502(f)(1) of the FDCA that labeling bear adequate directions for use, and the requirement of compliance with CGMP under section 501(a)(2)(B) of the FDCA. In the remainder of this letter, we refer to your drug products that do not qualify for exemptions under section 503A as the “ineligible drug products.”\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigators noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. Your operator was observed conducting aseptic operations outside of a certified ISO 5 area. The filling of sterile drug products into syringes, which were not for immediate administration to patients, but for shipment to patients across the country, was conducted in the unclassified dispensary area by personnel in street clothes with no gloves donned.\n\n2. Your “IV Hood” used to produce drug products purporting to be sterile is located in an unclassified room. In addition, this hood has not been certified in over two years.\n\n3. Your personnel performing sterile operations have never conducted media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\n4. Your operator engaged in aseptic processing while wearing non-sterile gloves, street clothes, and with exposed skin within the ISO 5 aseptic processing area.\n\n5. Your personnel engaged in poor aseptic technique on multiple occasions during the processing of sterile drug products. For example:\n\na. An operator placed their gloved hands outside the ISO 5 work area repeatedly to retrieve supplies without sanitizing their gloved hands before re-entry into the ISO 5 hood.\n\nb. An operator failed to sanitize or change gloves after contact with non-sterile materials (e.g., face mask, trash can) during sterile processing.\n\nc. An operator blocked first air by placing gloved hands directly in line with the sterile filter and open sterile containers.\n\n6. An operator was observed manually stoppering sterile drug vials and touching product contact surfaces during the process.\n\n7. Your firm exposed a stock solution intended to be sterile to worse than ISO 5 air after the stopper had been punctured multiple times. Specifically, the stock solution was stored in an unclassified area for further use after the container closure system had been punctured multiple times, and therefore compromised, throughout the assigned expiry period.\n\n8. Your firm stores unused product vials in non-sterile plastic bags, which are allowed to be reused in sterile production. The vials stored in these bags are not (b)(4). Moreover, your firm’s temperature and time conditions used for (b)(4) of product vials are not known to be (b)(4) microorganisms.\n\n9. Your firm has not conducted environmental monitoring since 2018.\n\n10. Your aseptic processing and surrounding areas had difficult to clean and visibly dirty equipment or surfaces. For example:\n\na. HEPA filters were discolored and\u002For damaged in the ISO 5 cleanroom hood.\n\nb. Your ISO 5 cleanroom workbench was constructed of laminated wood.\n\nc. A heating vent located below the ISO 5 cleanroom hood was visibly dirty and had no filtering device.\n\n11. Your firm handled hazardous drugs without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\n\nFurthermore, the manufacture of the ineligible drug products is subject to FDA’s CGMP regulations, Title 21, Code of Federal Regulations (CFR), parts 210 and 211. The FDA investigators observed significant CGMP violations at your facility, causing the ineligible drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations included, for example:\n\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\n2. Your firm failed to ensure that manufacturing personnel wear clothing appropriate to protect drug product from contamination (21 CFR 211.28(a)).\n\n3. Your firm failed to clean and sterilize and process, where indicated by the nature of the drug, container closures to remove pyrogenic properties to assure they are suitable for their intended use (21 CFR 211.94(c)).\n\n4. Your firm failed to establish a system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\n5. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)).\n\n6. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\n7. Your firm failed to prepare batch production and control records for each batch of drug product that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch (21 CFR 211.188(b)).\n\n8. Your firm failed to retest or reexamine components, as appropriate, for identity, strength, quality, and purity and your quality control unit failed to approve or reject components (21 CFR 211.87).\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for the ineligible drug products that you compounded.3 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\n\nMisbranded Drug Products\n\nThe ineligible drug products you compounded are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.4 Accordingly, these ineligible drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483. We acknowledge that your firm voluntarily ceased sterile production while corrective actions are implemented and, on (b)(4), initiated a voluntary recall of all compounded sterile products within expiry due to a lack of sterility assurance.\n\nRegarding your responses related to the insanitary conditions, some of your corrective actions appear adequate. Furthermore, we acknowledge your intention to install new modular cleanrooms in a separate building on your property to be used for sterile operations in the future. However, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation. For example:\n\n1. Your response to multiple observations includes the creation or revision of procedures and\u002For personnel training. None of the pertinent documentation was provided.\n\n2. You committed to the cessation of pre-filling syringes for shipment to patients. Your response states that staff have been counseled and refresher training on proper aseptic technique would be completed, but no documentation related to this was provided.\n\n3. Your response states that (b)(4), but no further details about the kits were provided. It cannot be determined from the available information if the kits (b)(4).\n\n4. Your response states you intend (b)(4) building which will include (b)(4). No additional information or supporting documentation was provided regarding this renovation; no response updates have been received.\n\n5. Your response states your firm has implemented several corrections such as the (b)(4), and (b)(4). No supporting documentation was provided for those corrective actions. No additional information was provided related to the ISO 5 hood with the laminated work surface, which you stated you are (b)(4).\n\n6. Your response states that you plan to (b)(4), but intend to (b)(4). However, no information was provided about the type of equipment and proposed timeline for this corrective action.\n\n7. Your response states that you would (b)(4) which would be more conducive to maneuvering in the cleanroom. It is unclear whether this is referring to (b)(4) to go inside the hood or beside the hood. If inside, dynamic smoke studies have not been provided to evaluate the effect of the (b)(4) on laminar airflow.\n\nIf outside the hood, employees may continue to have issues reaching in and out of the hood to retrieve needed supplies during sterile operations.\n\n8. Your response did not provide sufficient detail for an evaluation of your corrections related to the handling of hazardous drugs to prevent cross contamination.\n\n9. Your response refers to staff members responsible for administering IVs being allowed to (b)(4). It is unclear which staff members this refers to, where this operation is to occur, and whether those employees will also be conducting (b)(4).\n\nYou did not address certain observations related to insanitary conditions, for example:\n\n1. Your response states that (b)(4) building on the property. The response does not address how or if the current ISO 7\u002F8 suite of rooms will be used in the future.\n\n2. Your response states that (b)(4) units to be installed but does not address the (b)(4) monitoring in your current classified areas.\n\n3. Your response did not address the lack of (b)(4) by your operators during aseptic production.\n\n4. Your response failed to address your lack of routine environmental monitoring.\n\n5. Your response did not address what actions, if any, were taken to ensure the IV hood located in the unclassified room is no longer used.\n\n6. Your response did not address the cleaning and mitigation of the visible drug residues on your current shared equipment that was observed during the inspection.\n\nRegarding your responses related to the insanitary conditions, the following corrective actions appear deficient:\n\n1. Your response states that opened vials will (b)(4) from opening or the date of expiry and the vials will only be (b)(4). Your response did not provide justification for (b)(4). It is unclear if the stoppers for your stock vials, which are prepared in house, are intended for (b)(4). Your response states that employees have been instructed to visually inspect stock solution vials. Visual inspection of (b)(4) vials is not a suitable indicator that the product remains sterile. Your response does not demonstrate how you will prevent contamination when (b)(4), with or without use of (b)(4), are stored outside of an ISO 5 environment.\n\n2. Your firm uses (b)(4) drug product vials; however, your response states you are (b)(4), which would not be suitable for use in (b)(4). It is unclear whether your firm has purchased (b)(4) for sterilization of the product vials. Your response does not address the (b)(4) of product vials. You provided no information demonstrating that the current (b)(4) cycle is adequate. Your response does not address the use of (b)(4) during sterilization or (b)(4) during (b)(4). The use of vials that have not been adequately (b)(4), even if adequately sterilized (b)(4), is not an acceptable practice.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503A, the compounding and distribution of such drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the drug CGMP regulations. Before doing so, you must comply with the requirements of section 505 and 502(f)(1) and fully implement corrections that meet the minimum requirements of the CGMP regulations.5\n\nIn addition, it appears you may have been compounding using the bulk drug substance piracetam. Drug products compounded using bulk piracetam are not eligible for the exemptions provided by section 503A(a), because piracetam is not the subject of an applicable USP or NF monograph, not a component of an FDA-approved human drug and does not appear on the 503A bulks list.\n\nFurthermore, it appears that your facility may have produced biological products. Please be advised that federal law does not provide a legal pathway for marketing biological products that have been prepared outside the scope of an approved biologics license application (BLA). Specifically, section 351(a)(1) of the Public Health Service Act (PHS Act) prohibits the introduction into interstate commerce of any biological product unless “a biologics license . . . is in effect for the biological product” (i.e., an approved BLA). Additionally, biological products subject to licensure under section 351 of the PHS Act are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. We also note that, as required by the Biologics Price Competition and Innovation Act of 2009, on March 23, 2020, an approved application for a biological product under section 505 of the FDCA was deemed to be a license for the biological product (i.e., an approved BLA) under the PHS Act. This transition affects compounding under sections 503A and 503B of the FDCA because, beginning on March 23, 2020, these biological products that previously could have been submitted in a marketing application under the FD&C Act are subject to licensure under section 351 of the PHS Act and thus are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. See Notice to Compounders: Changes that affect compounding as of March 23, 20206 and section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 for additional information. Although these biological products are not eligible for the exemptions in sections 503A and 503B, FDA issued guidance explaining the conditions under which we do not intend to take action when certain biological products are mixed, diluted, or repackaged in a manner not described in their approved labeling. See Guidance for Industry: Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application (available at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F90986\u002Fdownload).\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b)].\n\nFDA strongly recommends that if you decide to resume production of sterile drugs, your management first undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\n\nLastly, during the inspection, investigators noted that your firm may be exporting products to other countries. Please be advised that if a product meets the FDCA’s requirements for sale and distribution in the United States, the FDCA has no additional restrictions on its exportation (i.e., sections 801 and 802 of the FDCA [21 U.S.C. § 381 and 382] do not apply to such exports). However, if the product does not meet FDCA’s domestic marketing requirements and is intended for export then you are required to be in compliance with applicable sections of the FDCA Chapter VIII – Imports and Exports. Furthermore, other federal statutes or regulations administered by other federal agencies (such as the Department of Commerce) may apply. For further information please see FDA’s Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 (available at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-exports-under-fda-export-reform-and-enhancement-act-1996).\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nIf you decide to resume sterile operations, you should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing if you have taken any specific steps to address any violations, or you may inform us that you do not intend to resume production of sterile drugs. If you intend to resume production of sterile drugs in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any sterile drugs in the future.\n\nYour written notification should refer to the Warning Letter Number above (615908). Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Tina M. Pawlowski, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations Division III\n\nIf you have questions regarding the contents of this letter, please contact Tina M. Pawlowski at (313) 393-8217.\n\nSincerely,\n\n\u002FS\u002F\n\nNicholas F. Lyons\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations Division III\n\n______________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n\n2 On June 9, 2016, FDA issued a final guidance titled, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. This guidance describes FDA’s interim regulatory policy for State-licensed pharmacies, Federal facilities, and licensed physicians that compound human drug products using bulk drug substances that do not otherwise meet the conditions of section 503A(b)(1)(A)(i) while the 503A bulks list is being developed. Specifically, the guidance sets out the conditions under which FDA does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug, until the substance is identified in a final rule as included or not included on the 503A bulks list. These conditions include that the substance may be eligible for inclusion on the 503A bulks list, was nominated with adequate support for FDA to evaluate it, and has not been identified by FDA as a substance that appears to present significant safety risks pending further evaluation. Cerebrolysin, thymosin alpha, thymosin beta, BPC-157, LL-37, pentosan, Selank, and Semax were not nominated for inclusion on the 503A bulks list. For additional information, see the guidance at http:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM469120.pdf.\n\n3 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) [21 U.S.C. 321(p)] of the FDCA because they are not generally recognized as safe and effective for their labeled uses.\n\n4 Your ineligible drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\n\n5 In this letter we do not address whether your proposed corrective actions would resolve the CGMP violations noted above.\n\n6 Available at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fnotice-compounders-changes-affect-compounding-march-23-2020.","Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine","advanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-nutriceuticals-llc-dba-guyer-institute-molecular-medicine-615908-11102021","2026-10-26T08:07:50.520086+00:00","Closed Out","2021-11-16","615908","2026-03-17","Leonard D. Guyer, MD","2026-08-20T02:26:18.165+00:00","UPS Next Day","2021-11-10",8,{"510k":171,"classification":172,"enforcement":173,"event":174,"event_backfill":175,"pma":176,"warning_letter":177},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]